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Abstract 
 Pim (Provirus Integration site for Moloney murine leukemia virus) kinases 
are a family of three serine/threonine kinases involved in cell cycle, survival and 
metabolism.  These kinases were first identified in malignant cells and are most 
often associated with their role in cancer. Their role in immunity and lymphocytes 
is less well known. To date, it has been shown that Pim 1 and/or Pim 2 are 
important for T lymphocyte survival and activation when the Akt signaling 
pathway is inhibited by rapamycin. In addition, our laboratory has shown that Pim 
2 is critical for BLyS-mediated naive B lymphocyte survival in the presence of 
rapamycin.  
 This thesis extends the role(s) for Pim 1 and/or 2 to include functions 
during B cell activation and the generation of immune responses. We found that 
during in vitro activation of purified resting splenic B cells from wild type mice with 
a variety of activators that use multiple signaling pathways, including the BCR, 
TLR and CD40 receptors, both Pim 1 and 2 kinases were induced by 48 hours 
post-activation, suggesting that they could play a role in B cell activation and 
differentiation to antibody secreting or memory B cells. Immunization of  
Pim 1-/-2-/- knockout mice with T cell dependent antigens showed impairment in 
antibody and antibody secreting cell generation as well as lack of germinal center 
formation clearly demonstrating an involvement of Pim 1 and/or 2 in the immune 
response. FACS examination of B cell populations from naive Pim 1-/-2-/- 
knockout mice revealed normal levels of splenic marginal zone and follicular B 
cells and T cells, however, decreased numbers of all peritoneal B cell 
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populations and decreased B cells in Peyer's Patches was seen. An examination 
of serum antibody found in naive Pim 1-/-2-/- knockout mice showed decreased 
levels of natural antibody, which is likely due to loss of the peritoneal B1 cells but 
does not explain the significantly decreased TD immune response. To determine 
whether the defect was B cell intrinsic or a more complex interaction between B 
and T cells, we determined whether Pim 1-/-2-/- mice would respond to T cell 
independent, TI-1 and TI-2, antigens. Antibody production and antibody secreting 
cell formation were also significantly decreased in these mice supporting our 
notion of a B cell intrinsic defect. To further examine the B cell response problem, 
we attempted to establish chimeric mice using either bone marrow derived cells 
or fetal liver cells from WT or Pim 1-/-2-/- donors so that the B cells were derived 
from Pim 1-/-2-/- mice and the T cells would be WT. Unfortunately, we were not 
able to consistently engraft and develop mature Pim 1-/-2-/- B cells, which indicate 
that there is a stem cell defect in these knockout mice that requires further 
investigation. Because one of the major failures in activated Pim 1-/-2-/- B cells is 
the generation of antibody secreting cells, an analysis of the expression of 
transcription factors IRF-4 and BLIMP-1, known to play a role in this process was 
carried out. Although IRF-4 induction was not affected by the loss of Pim 1 and 2, 
the number of cells able to increase BLIMP-1 expression was significantly 
decreased, revealing a partial block in the generation of ASCs. Taken together 
the data presented in this thesis reveals a new and critical role for Pim 1 and 2 
kinases in the humoral immune response.  
vii
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Chapter I 
Introduction 
 
 B cell development following gestation begins in the bone marrow when a 
common lymphoid progenitor commits to the B cell lineage by becoming a pro B 
cell. Thereupon follows a step-wise developmental and selection process 
producing sequentially a pre-B cell then an immature B cell that exits the marrow.  
Immature B cells transit from the bone marrow to the spleen where they mature 
through the transitional 1, 2, and 3 stages. It is during the transitional 2 stage that 
B cells become dependent on B Lymphocyte Stimulator (BLyS, also known as B 
cell Activating Factor (BAFF)), a cytokine in the tumor necrosis factor (TNF) 
family, for survival. Transitional B cells express two different BLyS receptors, 
BLyS receptor 3 (BR3) and transmembrane activator and calcium modulator and 
cyclophilin ligand interactor (TACI). A third receptor, B cell maturation (BCMA) is 
expressed after B cell activation and is critical for the survival of long-lived 
antibody secreting cells (1-3). In the final step of B cell development a transitional 
immature B cell becomes either a Marginal Zone (MZ) or Follicular B cell (Fo); 
these B cell subsets have different functions discussed below and can be 
identified by differing expression of cell surface phenotypic markers such as 
CD21, CD9, CD1d, and CD23 (4).   
A number of functional differences, aside from phenotype, distinguish 
these two naïve mature B cell subsets. The types of immune responses are 
explained in detail later, but Fo B cells are considered the main B cells involved 
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in both T cell dependent (TD) and T cell independent type 1 (TI-1) responses.   
When activated by a specific TD antigen Fo B cells generate extrafollicular short-
lived antibody secreting cells and germinal centers (GC) that give rise to long-
lived ASCs and memory B cells. Marginal zone B cells respond primarily and 
rapidly to T cell independent type 2 (TI-2) antigens that traffic into the spleen 
from the blood and generate short-lived plasma cells, with certain exceptions (5, 
6). MZ B cells can also transport antigen to the follicle where GC reactions 
develop (7). MZ B cells quickly increase BLIMP-1 expression and differentiate 
into plasma cells after activation, which has been demonstrated in vitro (8). This 
is likely due to the fact that resting MZ B cells contain more endoplasmic 
reticulum, express higher levels of BLIMP-1 and lower levels of Bcl-6 than their 
follicular counterparts (8). These cellular and molecular characteristics are 
reminiscent of antibody secreting cells (ASC); and suggest that MZ B cells are in 
a “heightened” state of activation compared to Fo B cells.  
Another subset of B-lymphocytes, B1 cells, are found in the peritoneal and 
pleural cavities as well as the spleen and can migrate to the intestine (5, 9).  As 
with MZ B cells, B1 B cells are poised to rapidly differentiate into ASCs without T 
cell help (6). B1 B cells have the unique ability to self-renew and have less BCR 
diversity than splenic B cells and are considered the source of natural antibody 
(5, 9). B1 B cells can be further divided into B1a and B1b cells, which have been 
shown to have different but complimentary roles in the humoral immune system. 
B1a B cells often produce natural antibodies, which provide the first line of 
defense against infection, while B1b B cells can generate antibodies in response 
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to infection (10, 11). Natural antibody forms the first layer of protection against 
invading pathogens. B1b cells can be activated quickly when encountering 
antigen and have been shown to be the first B cells to produce antibody against 
the cell wall of an invading bacteria. Therefore, while B1a B cells may 
spontaneously differentiate into plasma cells and produce natural antibody, which 
is useful against many pathogens, B1b cells respond quickly in a cognate manor 
to a specific pathogen to produce antibody against that particular pathogen (5, 9, 
11, 12). 
All B cell subsets participate in the humoral immune response, in which B 
cells produce antibodies against an immunization or invading pathogen and stem 
the spread of disease. There are three types of immune responses resulting in 
the production of antibody against a pathogen, T cell dependent (TD), T cell 
independent type I (TI-1), and T cell independent type 2 (TI-2).  The type of 
response elicited depends on the pathogen and the accessory cells participating 
in the response. A TD antigen will only generate an antibody response if T cells 
are present to assist in B cell activation. T cells facilitate the differentiation and 
proliferation of B cells activated by antigen. TD responses induce ASCs via two 
pathways. An extra-follicular response results in a quick increase in antibody 
against the antigen.  Alternatively, activated B cells enter a splenic or lymph node 
follicle and form a GC where B cells proliferate rapidly and differentiate into ASCs 
as well as memory cells (6).  Germinal centers are also the site of isotype 
switching (13) and the selection of high affinity ASC and memory B cells. B cells 
expressing different isotypes, generated by switching, have varying effector and 
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trafficking mechanisms associated with the non-antigen binding Fc portion of the 
immunoglobulin. Affinity maturation ensures that antibody generated later in the 
immune response will have a higher affinity than early antibody (14, 15). 
TI immune responses results in B cell activation without the requirement 
for cognate T cell help, as the name suggests. In vivo they arise earlier than TD 
responses, as there is no need for expansion or priming of cognate T cells, and 
play an important role against many extracellular pathogens. There are two types 
of antigen, which activate B cells in a T cell independent manner. A TI type 1 (TI-
1) antigen contains epitopes recognized by the BCR as well as ligands that can 
engage pattern recognition receptors. Unlike TD and TI-2 antigens, TI-1 antigens 
are directly mitogenic, such that at high concentrations of antigen, B cells 
proliferate and generate ASCs regardless of their BCR specificity by binding of 
the TI-1 antigen to pattern recognition receptors such as CD14, and TLR4. At low 
concentrations, a TI-1 antigen activates only those B cells specific for the 
antigen, resulting in an antigen specific response. TI type 2 (TI-2) antigens have 
a highly repetitive structure and can only activate B cells specific to that antigen. 
This response is generally thought to occur extra-follicularly though there is some 
evidence for a short-lived germinal center response (6, 16).  
  Humoral immune responses occur not only in the spleen or peritoneal 
cavity, but also in other secondary lymphoid sites, including the lymph nodes and 
intestine. The intestine is open to the environment and requires constant 
monitoring and quick responses to foodborne pathogens. Peyer’s Patches (PP), 
follicles in the intestine wall that contain lymphocytes, macrophages, and 
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dendritic cells are the primary sites for lymphocyte activation by environmental 
stimulation.  Germinal centers and isotype switched B cells are found in PP, 
similar to TD antigen driven responses in the spleen. Unlike the spleen where 
IgG is the dominant isotype, IgA is the dominant isotype in mucosal defenses 
including Peyer’s Patches (16).   
Irrespective of the mode of activation, B cells must differentiate into 
antibody secreting cells to produce the antibody that is the basis of humoral 
immunity.  This differentiation involves a tightly regulated specific genetic 
program, which has only been partly elucidated.  The most well known critical 
transcription factor associated with ASC differentiation is B Lymphocyte induced 
maturation protein 1 (BLIMP-1), the loss of which severely impacts ASC 
generation (17), whereas over expression can spontaneously induce ASC 
differentiation (18). Immunization of conditional BLIMP-1 knockout mice with TD 
and TI-2 antigens resulted in very few ASCs (17).  In vitro, BLIMP-1-/- B cells 
stimulated with LPS proliferated normally but did not generate ASCs. 
Immunization of mice whose B cells lack BLIMP-1 revealed a 3-fold decrease 
and 10-fold decrease in ASCs to TD and TI-2 antigens (17). IRF4 is another key 
transcription factor induced upon B cell commitment to the ASC lineage, which 
precedes BLIMP-1 induction. There is contradictory evidence of a direct linear 
relationship between IRF-4 and BLIMP-1 expression as one study found that 
IRF-4-/- B cells stimulated in vitro with LPS expressed BLIMP-1 normally (19) 
while another study found that IRF-4-/- B cells were unable to induce BLIMP-1 
under the same conditions (20). Consistent with its role in ASC development, 
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IRF-4-/- B cells generate 95% fewer ASCs than WT B cells when activated 
polyclonally in vitro, and there are very few CD138+ IRF4-/- B cells induced by 
immunization with TD antigens compared to control B cells (19, 20). A third 
transcription factor critical to ASC generation is XBP-1 (21). B cells lacking either 
IRF-4 (19) or BLIMP-1 (17) are unable to induce expression of XBP-1, 
demonstrating that XBP-1 depends on the expression of both IRF-4 and/or 
BLIMP-1. Although in vitro experiments revealed that survival and proliferation 
were unaffected in XBP-1-/- B cells after 4 days with LPS stimulation, XBP-1 
deficient mice had 70-fold fewer ASCs, and virtually absent IgM and IgG3 
antibody responses to immunization with TI-2 and TD antigens respectively (21).  
Pim 1, Pim 2, and Pim 3 kinases comprise a family of proto-oncogenes, 
which promote cell cycle and protein synthesis while suppressing apoptosis. The 
Pim kinases have a conserved kinase domain but no regulatory domain and are 
thought to be constitutively active once expressed (22). Pim-1 (23) and Pim-2 
(24) were first identified as frequent proviral insertion sites in murine leukemia 
virus induced lymphomas. Pim kinases are highly homologous; Pim 2 and Pim 3 
share 61% and 71% amino acid identity with Pim 1 respectively (25). Pim 1, 2, 
and 3, also share a common phosphorylation consensus sequence (26) while 
Pim 1 and 2 display substrate specificity with a strong preference for basic 
residues (27-29). All three are serine/threonine kinases (30) that act downstream 
of cytokine and other receptors affecting several aspects of cell function, 
including but not limited to, induction of transcription factors NFAT and c-Myb, 
stabilizing proteins such as SOCS, suppressing apoptosis by inducing Mcl-1 
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while inhibiting BAD, and promoting cell cycle by inactivating p21 (31-33). All 
three Pims are transcriptionally regulated and have unique though sometimes 
overlapping tissue expression patterns (34-36). Pim kinases are found in the 
cytoplasm, though recent preliminary experiments in our lab have shown that 
Pim 1 and 2 can localize to the nucleus in B cells stimulated with LPS but not 
anti-CD40 and IL-4 suggesting that localization as well as Pim targets are 
dependent on upstream signaling.  
Only Pim 1 and Pim 2 are expressed in lymphocytes and both have been 
shown to play a role in growth and survival in these cells. Pim 1 is important in 
cell cycle progression (33, 37, 38). Pim 2 is involved in cell growth by increasing 
glycolysis (39, 40). Pims have been shown to be induced downstream of the 
Jak/STAT pathway after various stimuli. However, unpublished results from our 
lab demonstrate that Pim induction downstream of BLyS is not Jak/STAT 
dependent and therefore other pathways are also capable of inducing Pim. 
Although Pim induction downstream of BLyS has been linked to NF-kB2 
induction (41) this signaling pathway(s) continues to be an active area of 
investigation. Despite their role in these critical functions, mice with targeted 
mutations in Pim 1 and Pim 2 (Pim 1-/-2-/-) display no gross abnormalities. In vitro 
studies of lymphocyte survival have shown that Pim 1-/-2-/- B and T cells behave 
as WT unless treated with rapamycin, which blocks the Akt kinase pathway 
downstream at the level of mTOR.  WT T cells cultured with IL-4 or IL-7 survive 
normally with or without rapamycin treatment, whereas, Pim 1-/-2-/- and Pim 2-/- T 
cells do not survive when treated with rapamycin even in the presence of survival 
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cytokines, demonstrating that either Akt or Pim 2 are required for T cell 
resistance to spontaneous apoptosis. In vitro experiments further showed that 
Pim 1-/-2-/- and WT T cells responded similarly to multiple activators. However, 
Pim 1-/-2-/- T cells were unable to up-regulate cell surface activation markers and 
blastogenesis was suppressed in the presence of rapamycin demonstrating the 
involvement of Pim 1 and 2 in T cell survival and activation (42). A similar 
paradigm was demonstrated for B cells, WT or Pim 1-/-2-/- B cells cultured with 
BLyS resist spontaneous apoptosis, however, when the Akt survival pathway is 
blocked using rapamycin, Pim 1-/-2-/- and Pim 2-/- B cells do not survive. These 
results demonstrate the redundancy of Pim 2 and Akt pathways in BLyS 
dependent resistance to apoptosis (41). The role of Pim 1 and 2 during B cell 
activation or differentiation to antibody secreting cells, long-lived plasma cells or 
memory B cells is unknown. However, it is noteworthy that Pim 1 and 2 are 
known to play a critical role in cell metabolism, and in protein synthesis 
processes that are critical to the function of activated B cells.  
To investigate a possible role for Pim 1 or 2 in B cells post-activation, we 
used a genetic approach with Pim 1 and 2 deficient mice to assess the role of 
these kinases in regulating humoral immunity. Chapter III of this thesis 
demonstrates that Pim 1 and 2 are induced upon B cell activation by a wide 
variety of stimuli and documents reduced immunoglobulin found in unimmunized 
Pim 1-/-2-/- mice when compared to wild type controls. To investigate the cause of 
the immunoglobulin defect, we analyzed the resting B cell populations in a naïve 
Pim deficient mouse. MZ and Fo splenic B cell subpopulations were not 
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significantly impaired in number or proportion in Pim 1-/-2-/- mice. However, B1 B 
cells residing in the peritoneal cavity were decreased when either Pim 1 or 2 was 
lost. B1 B cells are the main contributors to natural IgG3, IgA, and IgM 
immunoglobulin of unknown specificity, which was lower in Pim deficient mice 
than WT mice. The loss of IgG3 and IgM natural immunoglobulin is consistent 
with the diminished peritoneal B1 B cells. However, B1 cells produce IgA not 
primarily in the peritoneal cavity but at mucosal surfaces such as Peyer’s patches 
found in the intestine. This led us to ask if the Peyer’s Patches of Pim 1-/-2-/- mice 
were affected by the loss of Pim 1 and 2. While the number of Peyer’s Patches in 
Pim 1-/-2-/- was not significantly different, however, the number of IgA switched B 
cells found in the Peyer’s patches was approximately 2-fold less in Pim 1-/-2-/- 
mice, closely matching the magnitude of the B1 deficiency found in the peritoneal 
cavity. Whether this B1 deficiency is due to a developmental or migratory defect 
is not explored in this work. Peyer’s Patches also contain GC B cells defined as 
B220+GL7+CD95+, in response to environmental stimuli, but this population was 
absent in Pim 1-/-2-/- mice.   
In addition we evaluated Pim induction in B cells activated by various 
stimuli. Although Pim 1 and 2 are induced with BLyS, anti-CD40, and anti-Ig 
activation of B cells (41), to the best of our knowledge, this is the first 
demonstration of Pim induction after activation with LPS, CpG, anti-delta-dextran, 
or a BCR-specific activator. Pim induction by a BCR-specific antigen is consistent 
with a critical role for Pim 1 and/or 2 during a B cell response to antigen. 
21
Chapter IV explores the deficiencies found in Pim 1-/-2-/- mice immunized 
with TD antigens. Antigen-specific antibodies as well as ASC numbers were 
significantly decreased. We also observed a diminished GC response under 
most circumstances. We found that using a stronger adjuvant or antigen 
increased the likelihood of Pim 1-/-2-/- mice having normal GC numbers. For 
example, immunization with SRBC resulted in half of the Pim 1-/-2-/- mice 
generating a GC response while the other half did not. This is consistent with the 
strength of the immunogen playing a key role in the ability of Pim 1-/-2-/- to form a 
GC. We hypothesize that the mechanism behind the decreased GCs is impaired 
signaling downstream of the BCR and CD40 due to the loss of Pim 1 and 2. As a 
result, alternative activation signals either downstream of these or other 
receptors must be stronger to reach a threshold of activation.  Consistent with 
this idea, the affinity of antigen specific antibody induced in Pim 1-/-2-/- mice is 
significantly higher initially than that of WT suggesting that only Pim 1-/-2-/- B cells 
with a high affinity for the antigen are activated. Despite this, we found that the 
anti-NP antibody in Pim 1-/-2-/- mice failed to increase in affinity during a TD 
response. This could be due to the impaired GC response, as affinity maturation 
is known to take place in the GC or it could be due to an intrinsic B cell defect. 
Both affinity maturation and isotype switching are AID dependent processes. In 
vitro Pim 1-/-2-/- B cells were unable to switch to certain isotypes to the same 
extent as WT B cells, consistent with an intrinsic B cell defect. The defect in both 
affinity maturation and isotype switching suggested that the loss of Pim 1 and 2 
might result in the deregulation of AID. We have shown that at the mRNA level 
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that AID transcription is unaffected by the loss of Pim 1 and 2, however, this does 
not rule out a post-translational defect. Our attempts to induce an effective TD 
response in Pim 1-/-2-/- mice by the addition of T helper cells were unsuccessful, 
demonstrating again an intrinsic B cell defect. 
To directly assess the activation of Pim 1-/-2-/- B cells in the absence of T 
cell help, we immunized Pim deficient mice with either TI-1 or TI-2 antigens. After 
i.p. immunization with a TI-2 antigen, antibody titers in Pim 1-/- and Pim 2-/- mice 
were diminished relative to WT mice but not to the extent observed in Pim 1-/-2-/- 
mice. Delivering the TI-2 antigen directly to the intact MZ by i.v. immunization 
rescued the antibody response in Pim 1-/- and Pim 2-/- but not Pim 1-/-2-/- mice, 
revealing a defect in the ability of Pim 1-/-2-/- MZ B cells to respond to antigen. To 
determine where this block occurred, we activated isolated splenic B cells from 
WT and Pim 1-/-2-/- mice in culture. Though early activation steps were intact, 
measured by the appearance of activation markers and proliferation, Pim 1-/-2-/- B 
cells failed to generate normal numbers of ASCs. Investigating the induction of 
key transcription factors in the ASC developmental program, we found that only a 
small fraction of Pim 1-/-2-/- were able to induce BLIMP-1 upon activation, which 
therefore impairs the generation of ASCs. Though we have not tested BLIMP-1 
expression directly during an in vivo immune response or during the 
differentiation of B1 B cells into ASCs in a naïve mouse, other groups have 
shown that BLIMP-1 is critical to ASC generation during responses to TD and TI 
antigens by Fo, MZ and B1 B cells (17, 43). These results lead to a model in 
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which impaired ASC generation by the failure to induce BLIMP-1 results in 
reduced Ig titers in naïve, and TD, and TI immunized mice.  
To establish the cellular basis for the TD response deficiency of Pim 1-/-2-/- 
mice, we attempted to generate chimera mice using mixtures of WT and Pim 1-/-
2-/- bone marrow or fetal liver. We found, described in Chapter VI, a defect in the 
ability of Pim 1-/-2-/- marrow cells to reconstitute lethally irradiated mice but that 
homing of Pim 1-/-2-/- splenocytes was not affected. Our results closely mimic 
those of another group that failed to rescue lethally irradiated recipients using 
Pim 1-/- bone marrow; which they attributed to a Pim 1 dependent CXCR4 
functional defect affecting stem cell trafficking (44). The loss of CXCR4, however, 
does not account for the failure of Pim 1-/-2-/- fetal liver cells to reconstitute 
lethally irradiated recipients because when CXCR4-/- fetal liver cells are 
transferred in high numbers reconstitution is not impaired (45). Intriguingly, 
BLIMP-1 expression results in the up regulation of CXCR4 (46) and the 
additional defect seen in Pim 1-/-2-/- compared to CXCR4-/- fetal liver cells may be 
due to unknown additional BLIMP-1 targets. Alternatively to a defect in migration, 
these results may be due to a defect in development, which can be overcome in 
the intact Pim 1-/-2-/- mouse but prevents Pim 1-/-2-/- bone marrow or fetal liver 
cells from competing with WT cells in the same environment.   
This dissertation provides an overview of B cell activation as affected by 
Pim kinases. We have revealed new and critical roles for these enzymes in 
humoral immunity and suggest additional avenues of investigation. 
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Chapter II 
Materials And Methods 
 
Mice  
C57BL/6 and B6.C-Igha Thy1a Gpila mice (aged 8-24 weeks) were originally 
purchased from Jackson Laboratories (Bar Harbor, ME). C57BL/6 mice were 
used as controls for C57BL/6 Pim 1-/-, 2-/-, and 1-/-2-/- deficient mice originally 
obtained from Dr. C. Fox (Jackson labs, Bar Harbor, ME) (42) generated from 
mice given by Paul Rothman (Columbia University, New York, NY) (47). Initially 
backcrossed to B6 by Dr. C. Fox, backcrossing was continued in our lab by 
Sarah Kenward. B6x129 F1 and B6x129 F2 mice were purchased from Taconic 
Labs and used as controls for B6x129 Pim 1-/-2-/- received from Dr. C. Fox 
(Jackson Labs, Bar Harbor, ME). Mice with BCR specificity to the synthetic 
polypeptide, Poly-L-(Tyr,Glu)-poly-D,L-Ala--poly-L-Lysine [(T,G)AL] were 
generated by electroporating immunoglobulin H and L chains derived from the 
15F6 hybridoma into 2x107 E14.1 ES cells. Recombinant ES clones were 
identified by southern blot and injected into blastocysts and the resulting knock-in 
mice were backcrossed to a 129/sv background. Aproximaely 80% of B cells 
generated by these mice express BCRs with both heavy and light chains specific 
to (T,G)AL. These mice, referred to at GT-GL knock-in mice, were generated and 
generously provided by Dr. J. Press (Brandeis University, Waltham, MA). 
C57BL/6 BLIMP-1gfp/+ mice were generously provided by Dr. T. Imanishi-Kari 
(Tufts University, Boston, MA). Construction of BLIMP-1gfp/+ mice by Dr. Nutt 
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(University of Western Sidney, Australia) has been described previously (48). 
Our lab bred C57BL/6 Pim 1-/-2-/- mice with BLIMP-1gfp/+ reporter mice to generate 
BLIMP-1gfp/+ Pim 1-/-2-/- mice. Spleens from IRF4-/- mice were provided by Dr. R. 
Ren (Brandeis University, Waltham, MA) and produced as previously described 
(49).  Drs. L. Berg and J. Kang, Univ. of Massachusetts Medical School provided 
respectively OT II, Rag2-/- mice whose T cells are specific to OVA and 
allotypically marked C57BL/6-Ly5.2 mice. Dr. R. Gerstein generously provided 
µMT mice with a mutation in IgM resulting in a loss of the mature B cell 
compartment originally constructed by Kitamura and colleagues as previously 
described (50). B6 Rag2-/-, and B6-Ly5.2-Cr from Dr. Kang or purchased from 
NCI (Frederick, MD) were used as recipients in adoptive transfers. In some 
experiments mice were irradiated using a 137Cs source (Atomic Energy of 
Canada Limited, Industrial Products, Toronto, Canada) 2-24 hours before 
adoptive transfer. All mice were bred and maintained in the animal facilities at the 
University of Massachusetts Medical School. All animal care and procedures 
were carried out in accordance to the Animal Welfare act and IACUC rules. 
Immunizations 
In experiments examining thymus dependent responses, animals were 
immunized with 50 µg NP-CGG (Biosearch technologies Inc, N-5055-5) in 100 µl 
of endotoxin free PBS mixed for at least 30 minutes 1:1 with Imject Alum 
(Thermo Scientific, #77161) or 10% v/v Sheep red blood cells (Triple J Farms, 
BLD300050) injected i.p.. For experiments examining thymus independent type 2 
responses, mice were immunized with 50 µg NP-Ficoll (Biosearch, #F-1420) in 
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200 µl PBS delivered either i.p. or i.v.. In experiments examining thymus 
independent type 1 responses mice were immunized with 25 µg of Fitc-LPS 
(055:5B) injected i.p.. Control mice were given phosphate-buffered saline (PBS, 
Invitrogen) or Imject Alum without antigen.   
B cell isolation 
Intact spleens were injected with Special balanced salt solution (SBSS, 10g 
glucose, .6g KH2PO4, 1.84g Na2HPO2 H20, 1.86g CaCl2 2H20, 4g KCL, 80g 
NaCl, 2g MgCl2 6H2O, 2g MgSO4 7H2O, 0.1g phenol red in 10 L H2O, pH 
adjusted to 7.2) supplemented with .3% BSA, 10 µg/ml penicillin, 10 µg/ml 
streptomycin, and 10 µg/ml gentamicin (SBSS+) before being disrupted by 
pressing between 2 glass slides. To eliminate red blood cells, the cell pellet was 
resuspended in 1 ml/spleen of SBSS supplemented with 1% FBS, 10 µg/ml 
penicillin, 10 µg/ml streptomycin, and 10 µg/ml gentamicin before 3 ml/spleen of 
Gey’s solution (51) was added. After a 3-minute incubation cell suspensions 
were again washed with SBSS+ solution described above and enumerated by 
trypan blue and hemocytometer. T cell depletion was accomplished by incubating 
splenocyte suspensions with anti-Thy1.2 mAb (clone J1J10) on ice for at least 
thirty minutes followed by a wash with SBSS+. Mouse adsorbed rabbit 
complement (Pel-Freeze, 31042-2) was added to the suspension at 1:12 with 
cells at 50 million/ml. Suspensions were left shaking in a 370 water bath for thirty 
minutes then washed again. In some experiments small resting B cells were 
isolated after this step by fractionation on a Percoll (Sigma, P1644) step gradient 
(50, 65, 70, 75%) prepared in Hank’s balanced salt solution (HBSS, Sigma, 
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55021-C). Cultured B cells were kept in RPMI supplemented with 10% FBS 
(Gibco), 2 mM glutamine, 50 µM 2-mercatoethanol, 10 µg/ml penicillin, 100 µg/ml 
streptomycin, 10 µg/ml gentamicin and MEM nonessential amino acids (RPMI 
CM) then stimulated or not with LPS 055:B5 (10 µg/ml, Sigma, L2880), anti-IgM 
(10 µg/ml Jackson cat# 115-006-020), anti-CD40 (1 µg/ml eBioscience cat# 160-
402-85), CpG (1 µg/ml Invivogen, tlrl-modn-1), anti-delta-dextran (10 ng/ml, Fina 
Biosolutions LLC), TG4-Ficoll (1 µg/ml) (synthesized in the lab, basic protocol 
found in (51)), or B Lymphocyte Stimulator (BLyS 100 ng/ml, isolated from a 
transfected CHO cell line, provided by Dr. R. Noelle, Dartmouth Medical School). 
Peritoneal Cavity Cell Isolation 
Abdominal skin was removed to expose the peritoneal cavity of euthanized mice 
while not rupturing the cavity itself. Ten mls of SBSS+ was injected using a 21-
gauge needle. The body was massaged to move the fluid around the peritoneal 
cavity and dislodge any cells. Fluid was then removed from the cavity using a 
syringe and 18-gauge needle. Cell suspensions were spun down and treated 
with 1x Geys as needed to remove red blood cells (described above) then 
washed into FACS buffer and enumerated before cell surface staining as 
described below.  
Flow cytometry  
Cell Surface Staining  
 Cell suspensions in Hank’s Buffered Salt Solution (HBSS) supplemented with 
3% FBS and .02% azide (FACS buffer) were incubated on ice for 10 minutes with 
a mouse Fc receptor block against CD16/32 (clone 2.4G2) then surface stained 
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by incubating on ice for 30 minutes in the dark with antibodies against B220 (BD 
Pharmingen cat# 553093), CD19 (ebioscience 17-01091-81), CD93 (ebioscience 
cat# 175892-82), CD90.1 (ebioscience cat # 12-0900-81), CD90.2 (ebioscience 
cat# 17-0902), CD4 (Pharmingen cat#01084A or Caltag cat#RM2515), CD8a 
(Caltag cat# RM2204) and CD23 (ebioscience cat# 12-0232-83), GL7 (BD 
Bioscience cat# 553666), CD95 (BD Bioscience cat #554256 or ebioscience cat# 
12-0951-83), CD11b/Mac-1 (Biolegend cat#101230), CD43 (BDbiosciece 
cat#560663 or), CD5 (ebioscience cat# 12-0051-82), CD71 (Caltag cat# 
RM5304), CD69 (Caltag cat# HM4001), CD80 (ebioscience cat #12-0801-81), 
CD86 (ebioscience cat# 17-0862), CD21 (ebioscience cat# 11-0211), CD45.1 
(eBioscience cat#13-0453-81 or 13-0453-82), CD54.2 (Pharmingen cat# 553771 
or 553772), IgDb (BDpharmingen cat #553511), IgMb (Pharmingen cat# 05102D 
or 05105B), IgG1b (Pharmingen cat# 05172D), IgG2ab (Pharmingen cat# 
05032D), IgMa (Pharmingen cat# 05092D or 05094D), IgG1a (Pharmingen cat# 
5553502), IgG2aa (Pharmingen cat #05002D), IgDa (Pharmingen cat# 05064D), 
IgD (ebioscience cat # 11-5993 or southern biotech 1120-09), IgA (Southern 
Biotech cat # 1040-09). Antibodies used were directly conjugated to APC, 
PerCP, Fitc, or PE; in cases where the antibody was biotinylated the cells were 
washed in FACS buffer and incubated 30 minutes on ice with streptavidin-APC 
(eBioscience, 17-4317-82) or streptavidin-PerCP (BD pharmingen, 554064). 
After surface staining cells were washed twice with FACS buffer then 
resuspended in either 275 µl of 2% paraformaldehyde for fixed analysis or 300 µl 
of FACS buffer for live analysis. Cells were measured using Facs Calibur 
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instrument by the flow cytometry core facility at UMass Medical School and 
analyzed by Flowjo software (Treestar, Ashland, OR.). In all experiments 50,00-
200,000 events were collected. Dead cells were excluded based on forward and 
side scatter. 
IRF-4 Intracellular Stain 
Cultured B cells were collected and washed into 1xPBS + 0.5% BSA (FCM 
buffer).  2% paraformaldehyde was added 1:1 to create a final 1% solution. Cells 
were left at room temperature for 20 minutes. Cells were washed with 1xPBS + 
.5% BSA + .03% saponin (wash buffer) then resuspended in 25 µl of 1xPBS + 
.5% BSA + .3% saponin (perm/stain buffer) with 5 µl of donkey serum. Primary 
antibody was added at 1:20 either anti-IRF-4 (Santa Cruz biotechnology cat# sc-
6059) or normal goat IgG (Santa Cruz Biotechnology cat# sc-2028) and 
incubated for 20 minutes on ice. Samples were washed twice with wash buffer, 
resuspended in 100 µl of perm/stain buffer with 5 µl of normal donkey serum, and 
donkey anti-goat-fitc (Santa Cruz cat# sc-20204) secondary antibody was added 
1:100. Samples were incubated 20 minutes on ice then washed twice with wash 
buffer. Samples were resuspended in 300 µl of 2% paraformaldehyde then 
measured using Facs Calibur instrument by the flow cytometry core facility at 
UMass Medical School and analyzed by Flowjo software (Treestar, Ashland, 
OR.). In all experiments 200,000 events were collected. Dead cells were 
excluded based on forward and side scatter. 
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Cell Sorting 
 B cells isolated from C57BL/6 BLIMP-1+/gfp or C57BL/6 Pim 1-/-2-/- BLIMP-
1+/gfp mice were cultured for 4 days with 10 µg/ml LPS with or without 100 ng 
BLyS at 0.5x106/ml in RPMI supplemented with 10% FBS (Gibco), 2 mM 
glutamine, 50 µM 2-mercatoethanol, 10 µg/ml penicillin, 100 µg/ml streptomycin, 
10 µg/ml gentamicin and MEM nonessential amino acids. Cells were sorted 
based on GFP expression using either a Digital Vantage or Aria II instrument by 
the flow cytometry core facility at UMass Medical School and analyzed by Flowjo 
software (Treestar, Ashland, OR.). 
Cell labeling 
Splenic B and T or B cell suspensions 25x106 cells/ml were labeled with 10 µM 
CFSE (5-(and-6)-carboxyfluorescein diacetate, succinimidyl ester) (Molecular 
probes) in 1x PBS for 5 minutes at room temperature or 10 minutes shaking in a 
37°C water bath. Cells were washed twice with SBSS+BSA+P/S/G (defined 
above) then cultured in B cell media containing RPMI supplemented with 10% 
FBS (Gibco), 2mM glutamine, 50 µM 2-mercatoethanol, 10 µg/ml penicillin, 100 
µg/ml streptomycin, 10 µg/ml gentamicin and MEM nonessential amino acids. In 
migration experiments cells were washed and resuspended in endotoxin free 
PBS for I.V. injection.  
Cells capable of expressing GFP could not be labeled with CFSE as 
CFSE and GFP use the same FACS detection channel. As an alternative cells 
were labeled with cell proliferation Dye eFluor 670 (ebioscience). B cell 
suspensions were washed two times in 1xPBS and stained at 20x106 cells/ml 
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with 1.25 µM eFluor 670 in PBS for 10 minutes at 370 in the dark. After labeling 
cells 4-5 volumes of RPMI supplemented with 10% FBS (Gibco), 2 mM 
glutamine, 50 µM 2-mercatoethanol, 10 µg/ml penicillin, 100 µg/ml streptomycin, 
10 µg/ml gentamicin and MEM nonessential amino acids was added to the cell 
suspension which were then left on ice for 5 minutes. Cells were washed 3 times 
with the same RPMI solution and enumerated. Only B cells for culture were 
stained with eFluor 670 to track proliferation. 
Isotype Switching 
 B cells were isolated as described above or using a 75% Ficoll cushion in 
place of a step percoll gradient. Isolated B cells were cultured in RPMI 
supplemented with 10% FBS (Gibco), 2 mM glutamine, 50 µM 2-mercatoethanol, 
10 µg/ml penicillin, 100 µg/ml streptomycin, 10 µg/ml gentamicin and MEM 
nonessential amino acids with one of the following cytokine cocktails to induce 
switching to the isotype in parentheses; LPS+IL4+BLyS (IgG1), anti-
CD40+IL4+BLyS (IgG1), LPS+IL4+IL5+TGFβ+BLyS (IgA), LPS+INFγ+BLyS 
(IgG2a), LPS+TGFβ+BLyS (IgG2b), anti-CD40+TGFβ+BLyS (IgG2b), LPS+anti-δ-
dextran+BLyS (IgG3), or LPS (IgG3). IL4 (Peprotech) and IL5 (Peprotech) were 
used at 20 ng/ml, TGFβ (R&D systems) at 2 ng/ml and INFγ at 20 ng/ml 
(Perprotech). Cultures were collected on day 3 and the percent of switched B 
cells was measured by flow cytometry with cell surface antibodies against 
specific isotypes (described above).  
 
 
32
Adoptive Transfer 
Cells were washed twice in sterile PBS-BSA (0.3% w/v) then resuspended in 
endotoxin free PBS at the appropriate concentration. Cells (0.1-0.2 ml) were 
injected intravenous via the periocular sinus.  
Chimeras 
Recipient mice were either exposed to a single dose of 900 or 1200 rads 24 
hours prior to transfer, or a split dose of 1200 rads given as 600 rads 6 and 2 
hours prior to transfer, or were not irradiated. Bone marrow was collected from 
donor mice by flushing the hind leg bones with SBSS supplemented with 0.3% 
BSA, 10 µg/ml penicillin, 10 µg/ml streptomycin, and 10 µg/ml gentamicin then 
aspirating with a needle and syringe to break up clumps. Bone marrow cells were 
enumerated then washed in sterile PBS and resuspended in endotoxin free PBS 
at the appropriate concentration for transfer.  Fetal liver cells were collected on or 
about day 14 of gestation and pressed between 2 glass slides while submerged 
in RPMI supplemented with 10% FBS and pipetted to create a cell suspension. 
The fetal liver cell suspension was counted, washed in sterile PBS then 
resuspended in endotoxin free PBS at the appropriate concentration for transfer. 
ELISA 
Serum antibody specific for NP was assayed by an Enzyme-linked 
immunosorbant assay (ELISA); incubating serially diluted sera or control 
antibody on plates coated with NP7-9-BSA (synthesized in the lab, basic protocol 
found in (51)).  96 well polyvinyl chloride plates (Falcon) were coated with 10 or 
20 µg/ml of NP-BSA in PBS and left at least overnight at 4oC. Plates were 
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washed 8 times with PBS and blocked with 1% BSA PBS for at least 30 minutes 
at room temperature.  After dumping the blocking buffer serial dilutions of serum 
were incubated on the plate for 2 hours at room temperature or 4oC.  NP specific 
antibodies were detected with biotinylated anti-mouse IgM (Southern Biotech, 
1020-08), anti-mouse λ (Southern Biotech, 1060-08) or anti-mouse IgG1 
(Southern Biotech, 1070-08) specific reagents at 1:2000 dilution in 1% BSA PBS 
left for 2 hrs at room temperature or 4oC. To measure Fitc specific antibody in 
sera from mice immunized with Fitc-LPS, a Fitc-BSA plate coat was used at 20 
ug/ml in PBS and antibody was detected using an anti-mouse F(ab)2-biotin 
conjugate (Jackson ImmunoResearch, 115-066-072). Total IgG1, IgG3, and IgM 
antibody in naïve mice was measured using and anti-F(ab)2 (Jackson 
ImmunoResearch, 115-006-006) plate coat at 10 or 20 µg/ml and an isotype 
specific biotinylated detecting antibody described above or anti-mouse IgG3-
biotin (SouthernBiotech, 1100-08). Total IgA antibody in naïve mice was 
measured using an anti-mouse IgA (SouthernBiotech, 1165-01) plate coat at 
5 µg/ml followed by and anti-mouse IgA-biotin (SouthernBiotech, 1040-08) 
detecting antibody. For all assays washing off the detection antibody was 
followed by 1:4000 Strepavidin-Alkaline phosphatase (SA-AP) (SouthernBiotech, 
7100-04) in blocking buffer left 30-60 minutes at room temperature and washed 
off. 4-Nitrophenyl phosphate disodium salt hexahydrate (Sigma, N4645-5G) 
dissolved in 2-diethylalomine at 1 mg/ml was incubated on the plates until color 
had developed.  Optical density was determined at 405 nm on a department 
plate reader (Molecular Devices, Spectramax Plus 384). Relative antibody 
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concentrations were established by reference to a NP (Dr. T. Imanishi-Kari, 
Tufts), IgM (SouthernBiotech, 0101-01), IgA (SouthernBiotech, 0106-01), IgG3 
(Bionetics, 8402-28), or IgG1 (Bionetics, 8402-03) standard curve. For ELISAs 
measuring specific antibody after immunization serum from unimmunized mice 
was used as a background control. ELISAs measuring antibody in naïve sera 
used either µMT or rag1-/- sera as the background control.  
ELISpot 
To enumerate ASCs from splenocyte or cultured B cell suspensions, Milipore 
multiscreen HTS plates previously coated with 10 µg/ml of NP-BSA or anti-
mouse F(ab)2 (Jackson ImmunoResearch, 115-006-006) and left at least 
overnight at 4°C were washed eight times with water and blocked with RPMI 
supplemented with 10% FBS (Gibco), 2 mM glutamine, 50 µM 2-mercatoethanol, 
10 µg/ml penicillin, 100 µg/ml streptomycin, 10 µg/ml gentamicin and MEM 
nonessential amino acids for at least 30 minutes at 37°C. Cells were recovered 
from spleen, bone marrow, or in vitro cultures and enumerated as described 
above.  Serial dilutions of cells in RPMI were plated on previously antigen coated 
and blocked plates and incubated for 4 hours at 37°C. Plates were washed then 
blocked overnight at 4°C with 1% FBS in PBS before dumping the blocking buffer 
and adding the detection antibody, either biotinylated anti-mouse IgM (Southern 
Biotech, 1020-08), anti-mouse λ (Southern Biotech, 1060-08) or anti-mouse IgG1 
(Southern Biotech, 1070-08) specific reagents at 1:2000 dilution in 1% FBS PBS. 
Plates were incubated 3 hours at room temperature then washed with water. SA-
AP (Southern Biotech, 7100-04) diluted in 1% FBS PBS at 1:4000 was added to 
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each well. The plate was incubated 1 hour at room temperature then the fluid 
was dumped and the plates were washed eight times with water.  The substrate 
solution was made by dissolving one premeasured reaction mix (SIGMAFAST 
BCIP/NBT, Sigma, B565) in 10 mls of Millipore water then vortexing until 
completely dissolved. The resulting BCIP/NBT suspension was added to the 
plates and allowed to develop. When spots became visible the BCIP/NBT was 
removed, the plates were washed eight times with water dried and stored in the 
dark. Spots were enumerated using an ELISpot reader (CTL, Cleveland, OH) 
and analyzed with Immunospot software version 3.2 (CTL, Cleveland, OH). 
RNA extraction  
Cells collected from culture or sorted on the basis of GFP expression were spun 
down, dried by dumping the supernatant and absorbing left over moisture with a 
sterile q-tip then resuspended in 500 µl of TRI Reagent (Applied Biosystems, 
AM9738). Samples could be stored at -80oC at this step then thawed when RNA 
was to be isolated. 100 µl of Chloroform (Sigma 472476) was added to thawed 
tri-reagent samples, samples were shaken then incubated at room temperature 
for fifteen minutes. Samples were spun at 13,200 rpm at 4oC for fifteen minutes. 
All spins were done in a tabletop microfuge. The aqueous phase from each 
sample was transferred into a clean microfuge tube and 250 µl of isopropanol 
added.  Samples were vortexed for ten seconds, incubated at room temperature 
for ten minutes, and then spun at maximum speed for ten minutes at 4oC. 
Supernatant was discarded and 500 µl of 75% ethanol was added to each pellet. 
Samples were spun at 10,000 rpm at room temperature for five minutes. Ethanol 
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was removed and samples were air dried briefly. The pellet was resuspended in 
30 µl of RNAse free water. The concentration of RNA isolated from each sample 
was determined by measuring 1.5 µl of sample on a nanodrop 
spectrophotometer.  
Quantitative Reverse Transcription-Polymerase Chain Reaction 
cDNA was made as follows; one microgram of RNA from each sample was 
added to a clean tube and brought to a total volume of 15 µl with RNAse free 
water. Oligo dT primers (Promega) were diluted to a 5 µM working stock and 5 µl 
of this stock was added to each sample. Samples were incubated at 65oC for 
twenty minutes. A master mix of the following proportions was prepared for each 
sample: .25 µl of 25 mM dNTPs, 5 µl of 5x Promega M-MLV Reverse 
transcriptase buffer (50 mM Tris-HCL pH 8.3, 75 mM KCL, 3 mM MgCL2, 10 mM 
DTT), .4 µl RNAsin (Promega), 1 µl M-MLV-Reverse transcriptase (Promega), 
and 3.35 µl RNAse free water. The samples were then incubated at 42oC for an 
hour. The resulting cDNA was stored at -20oC. The quantitative polymerase 
chain reaction was performed using Roche Sybr Green master mix (Roche) with 
primers diluted to 30 µM, 5 µl of cDNA template, and RNAse free water to bring 
the final volume to 50 µl per reaction. The following primers were purchased from 
integrated DNA technologies; BLIMP-1 F 5’-GACGGGGGTACTTCTGTTCA-3’ R 
5’-GGCATTCTTGGGAACTGTGT-3’ XBP-1 F 5’-GAGTCCGCAGCAGGTG-3’ R 
5’-GTGTCAGAGTCCATGGGA-3’ Mcl-1 F 5’-
TCAAAGATGGCGTAACAAACTGG-3’ R 5’-CCCGTTTCGTCCTTACAAGAAC-
3’. B-Actin F 5’-CCCTAAGGCCAACCGTGAA-3’ R 5’-
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CAGCCTGGATGGCTACGTACAAG-3’ was generously provided by Dr. R. 
Gerstein. Relative levels of gene expression were established by qPCR with 
specific primers using in a Gene Opticon 2 machine generously shared by Brain 
Ackerly, University of Massachusetts Medical School.  
Immunohistochemistry   
Spleens from immunized, naïve, and alum control mice were harvested and 
preserved in formalin. Sections were cut, fixed with acetone, and stained with 
antibodies as indicated, by the DERC core facility at UMass Medical School. 
Germinal centers were identified under a light microscope at 4x by binding to 
biotinylated PNA followed by an immunohistochemical reaction using horseradish 
peroxidase avidin D (vector labs, a-2004) described at 
http://www.umassmed.edu/morphology/protocols/immunohistochemistry.aspx. 
PNA+ positive germinal centers over 2 separate spleen sections were 
enumerated by eye.   
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Chapter III 
Unimmunized Pim 1-/-2-/- Mice Have Impaired 
Natural Immunity 
 
Introduction  
B Lymphocytes are the effectors of humoral immunity; each has its own BCR 
specificity. As a result, a large pool of naïve mature B cells must be maintained in 
secondary lymphoid organs to ensure that when an antigen is encountered, a 
subset of B cells will respond to it in a cognate fashion and mount a humoral 
response. These naive B cells rely on B Lymphocyte stimulator (BLyS) for 
survival (1-3).  Previous work from our lab has shown that BLyS dependent 
survival of naïve B cells depends upon two signaling pathways, one acting 
through Akt kinase, and the other through Pim 2 kinase (41). A previous paper 
documented a delay in B cell development that disappeared by 12 wks in  
Pim 1-/-2-/-3-/- as assessed by spleen cell analysis and normal splenic B cell 
numbers in Pim 1-/-2-/- mice (52). However, our lab has observed diminished 
splenic B cells numbers in the Fo compartment in Pim 1-/-2-/- mice (41). These 
conflicting reports indicated that a more thorough analysis of B cell populations 
the Pim 1-/-2-/- deficient mice was needed, which is provided in this chapter.  
A second pool of mature B cells capable of producing antibody is found in the 
peritoneal cavity.  Splenic B cells are primarily B2 cells with a small population of 
B1 cells; in contrast, B cells in the peritoneal cavity are mostly B1, with a small 
cohort of B2 B cells. The development of these two B cell subpopulations 
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remains the subject of some debate, with some evidence pointing to different 
origins in either the fetal liver or bone marrow.  Chimeric mice produced by the 
transfer of fetal liver reconstitute the peritoneal B1 cell compartment more 
efficiently than transferred bone marrow.  The reverse is true of splenic mature 
B2 cell reconstitution. Some success has been reported in generating peritoneal 
B1 cells from adoptively transferred bone marrow (53) suggesting that a B1 cell 
precursor is not only found in the fetal liver. B1 and B2 cells are mainly 
distinguished by differing expression of specific cell surface markers. Whereas 
B1 and B2 cells have long been know to differ in their phenotypic expression it 
has only recently been revealed that B2 and B1 cells in the peritoneal cavity 
differ from their respective counterparts in the spleen (54). Function is another 
characteristic separating peritoneal and splenic B cells.  Peritoneal B cells have a 
lower activation threshold and are often activated and producing antibody in a 
non-immune mouse (6).  Production of this "natural antibody" is mainly attributed 
to peritoneal B1a B cells (11, 55, 56).  
B1 cells also migrate from the peritoneal cavity to the intestine, which is 
exposed to the environmental microflora and constantly under immunological 
surveillance. Protection against environmental pathogens in these areas is 
referred to as mucosal immunity and lymphocytes are primarily localized in 
Peyer’s Patches which are organized secondary lymphoid areas on the intestinal 
wall containing macrophages, dendritic, B and T cells. Germinal centers initiated 
by environmental stimulation largely contain B cells expressing the IgA isotype, 
the dominant isotype in mucosal immunity.  
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The role of Pim 1 and 2 in the maintenance of B cells and humoral 
immunity in naïve mice is poorly understood. Reports on the numbers of splenic 
B cells have been contradictory and to date no analysis of the B1 compartment 
or natural immunity of naïve Pim 1-/-2-/- mice has been published. In this chapter 
we present evidence that Pim 1 and 2 are critical for regulation of natural 
humoral immunity in naïve mice. While the numbers of splenic B cells are normal 
in Pim single and double deficient mice, the B1 cell peritoneal compartment relies 
on both Pims to achieve normal numbers. Whether this is due to impaired 
generation or maintenance of the B1 cell subset is not explored here. A 
consequence of the diminished B1 cell pool is diminished natural Ig, which is 
produced by B1a cells. We also find that mucosal immunity in the Peyer’s 
Patches is compromised. It has been suggested that B1 cells migrate from the 
peritoneal cavity to the gut and back so a deficiency in the number of B1 cells in 
the peritoneal cavity of Pim 1-/-2-/- is most likely linked to the decreased mucosal 
immunity in the gut. These data demonstrate the requirement for Pim 1 and 2 for 
the generation or maintenance of humoral immunity in naïve mice. 
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Results 
Mature splenic B cell subsets are not impaired by the loss of Pim 1 and/or 2 
To determine if the number and subpopulations of resting mature splenic B 
cells were intact in Pim 1-/-2-/- mice, we examined them using FACS analysis. 
Spleens were dissociated and red blood cells were lysed, total mature B cells 
were identified as B220+ AA4.1- then further subdivided into marginal zone 
(CD23lo CD21hi) or follicular (CD23hi CD21lo) B cells.  Our first experiments were 
performed on B6x129 mixed background mice. When examining the absolute B 
cell number in these mice, we observed that Pim 1-/-2-/- mice have a 60% 
reduction in the number of total and follicular B cells.  The marginal zone B cells 
were not significantly different (Figure 3.1 A). Our experiments using purchased 
B6x129 F1 mice as controls, were consistent with published results on this 
background that used littermate controls (41). 
We repeated these analyses with Pim 1-/-2-/- mice that were fully backcrossed 
(more than 10) to the C57/BL6 strain. Unlike the results with the mixed 
background, the absolute numbers and subpopulations of B cells in the DKO 
were not different than wild type B6 mice (Figure 3.1 B). Splenic B cell analysis in 
single knockout B6 backcrossed Pim 1 (Pim 1-/-) or Pim 2 (Pim 2-/-) were the 
same as the B6 Pim 1-/-2-/- and no different than wild type (Figure 3.1 B). Though 
these results were contrary to what we observed in our mixed background mice, 
collaborators in Dr. Cancro’s lab at the University of Pennsylvania confirmed our 
observation.
 Splenic T cell subpopulations were also examined in control and  
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Pim 1-/-2-/- mice. CD8+ T cells were present but significantly decreased in  
Pim 1-/-2-/- after compiling 2 experiments. CD4+ T cells were not significantly 
different consistent with T cell help being intact during the response to a TD 
antigen. Neither Pim single knockout mouse had any impairment.  
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Figure 3.1. The loss of Pim 1 and 2 does not impair the number of mature 
splenic B cells. Splenocytes from B6x129 (A) or C57BL/6 (B) control and Pim 1-
/-2-/- mice were analyzed for total (B220+), Fo (B220+CD23hiCD21lo), and MZ 
(B220+CD23loCD21hi) B cells. (C) Gating strategy for parts A and B. Error bars 
are shown. WT n=21, Pim 1-/-2-/- n=14 in (B); WT n=19 Pim 1-/- n=9, Pim 2-/- 
n=11, Pim 1-/-2-/- n=23 in (C). Statistics were determined by Student’s t test 
*=p<.05, **=p<.01, ***=p<.001 
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Figure 3.2 The CD8+ T cell subset is diminished in Pim 1-/-2-/- mice. 
Splenocytes from C57BL/6 control, Pim 1-/-, Pim 2-/-, and Pim 1-/-2-/- mice were 
analyzed by flow cytometry for total (anti-thy1.2+), CD4 (anti-thy1.2+CD4+) and 
CD8 (anti-thy1.2+CD8+) T cell subsets. (A) Numbers of T cells in each subset (B) 
gating strategy for part A. Bars are the mean and standard deviation for each 
genotype, each symbols represents an individual mouse. WT n=7, Pim 1-/- n=5, 
Pim 2-/- n=5, Pim 1-/-2-/- n=6. Statistics were determined by Student’s t test 
*=p<.05, **=p<.01, ***=p<.001 
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Peritoneal Cavity B cells are diminished by the loss of Pim 1 or 2 
Peritoneal B1 B cells are important mediators of natural and adaptive 
immunity. To determine if the loss of Pim 1 and/or 2 would impact peritoneal B 
cell populations, we analyzed the subpopulations of B cells in peritoneal washes 
from normal and Pim 1-/-2-/- mice by flow cytometry.  We observed a significant 4-
fold reduction in the total number of peritoneal B (B220+) cells in Pim1-/-2-/- 
compared to B6 controls (1.3x106 ± .29 vs. 3.8x106 ± .49, p<.001) (Figure 3.3 A). 
Within this population B1a (B220+CD43+CD5+) B cells were also reduced 4-fold 
relative to B6 controls (.18x106 ± .03 vs. .97x106 ± .27, p<.01) (Figure 3.3 C). A 
second subpopulation of B1 cells, B1b B cells (B220+CD43+CD5-), which can 
produce antigen specific antibody and B cell memory in response to blood borne 
antigens (10, 57) were also decreased by 50% when compared to wild type mice 
(.31x106 ± .05 vs. 1.2x106 ± .32, p<.01) (Figure 3.3 D). Therefore, the loss of Pim 
1 and 2 results in a defect in two distinct peritoneal B1 cell populations. We noted 
that the reduction in the B1 subpopulations did not account for the differences in 
total peritoneal B cells we found between Pim 1-/-2-/- and B6 mice. Although the 
majority of B2 cells reside in the spleen and other secondary lymphoid tissues, a 
small population recirculates and can be found in the peritoneal cavity. As with 
B1 cells, B2 (B220+CD43-) B cells in the peritoneal cavity were decreased more 
than 3-fold, with 0.67x106 ± .12 B2 cells in Pim 1-/-2-/- mice compared to 2.8x106 ± 
.38 B2 cells in B6 controls (p<.001) (Figure 3.3 B).    
To determine which Pim kinase is critical for the maturation and/or 
maintenance of peritoneal B cell populations, we analyzed Pim 1 and Pim 2 
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single knockout mice.  Total peritoneal B cells were significantly decreased in 
both Pim 1-/- and Pim 2-/- mice (Figure 3.3 A). B1a cells in Pim 1-/- mice were 
decreased more than 2-fold with .36x106 ± .05 compared to .97x106 ± .2 in WT 
(p<.05) whereas Pim 2-/- mice were diminished but did not reach significance 
(Figure 3.3 C).  B1b cells in the single knockout mice followed the same pattern 
with a significant decrease, about 3-fold (p<.05), found in the Pim 1-/- mice. 
Although Pim 2-/- mice did not have a significant difference in the number of 
peritoneal B1 cells the mean was very close to Pim 1-/- and Pim 1-/-2-/- (Figure 3.3 
D). Only Pim 1 B1 cell numbers were significantly less than WT but the loss of 
Pim 2 does not result in normal B1 cell numbers suggesting that both Pims 
contribute to the generation or homeostasis of peritoneal B1 cells. Peritoneal B2 
B cells were significantly decreased in both Pim 1-/- (p<.001) and Pim 2-/- (p<.01) 
mice being reduced to less than a third of that seen in B6 mice (Figure 3.3 B).  
From these results we conclude that both Pim 1 and Pim 2 play a role in the 
development and/or maintenance of normal B cell numbers in the peritoneal 
cavity though the data suggests that Pim 1 may be more important than Pim 2.  
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Figure 3.3. Peritoneal B cell subsets are diminished in Pim deficient 
mice. Cells were isolated from the peritoneal cavity of control or Pim deficient 
mice and analyzed by flow cytometry. B cell subsets were identified as total 
(B220+) (A), B2 (B220+Mac-1-CD43-) (B), B1a (B220+Mac-1intCD43+CD5+) (C), or 
B1b (B220+Mac-1intCD43+CD5-) (D). (E) Gating strategy for A-D. Bars indicate 
means and SEM; each symbol represents an individual mouse, WT n=10, Pim 1-
/- n=12, Pim 2-/- n=10, Pim 1-/-2-/- n=12. Statistics were determined by Student’s t 
test *=p<.05, **=p<.01, ***=p<.001 
 
 
 
 
 
 
 
 
50
Peritoneal B cell subsets are diminished in Pim deficient mice 
 
A.       B. 
WT Pim 1-/- Pim 2-/- Pim1-/-2-/-
0
1
2
3
4
5
6
7
***
**
***
Total B cells in Per. Cavity
WT Pim 1-/- Pim 2-/- Pim 1-/-2-/-
0
1
2
3
4
5
***
***
**
Per. Cavity B2 cells
C.      D. 
WT Pim 1-/- Pim 2-/- Pim1-/-2-/-
0.00
0.25
0.50
0.75
1.00
1.25
1.50 *
**
B1a Per Cavity
WT Pim 1-/- Pim 2-/- Pim1-/-2-/-
0.0
0.5
1.0
1.5
2.0
**
*
B1b cells Per Cavity
B6 WT
B6 Pim 1-/-
B6 Pim 2-/-
B6 Pim 1-/-2-/-
 
51
 
 
 
 
 
 
 
E.
 
 
 
 
 
 
 
 
 
 
 
52
Natural antibody is impaired by the loss of Pim 1 or 2 
Peritoneal B cells are a major contributor to natural antibodies, found in 
healthy naive mouse serum that serves as a first line of defense against many 
environmental pathogens.  The source of this serum Ig has been mainly 
attributed to B1a cells (11, 55, 56), which we have shown are reduced in Pim 1-/-
2-/- mice.  We asked whether this reduction was enough to impair natural Ig in 
these mice. Serum from B6x129 control F1 and Pim 1-/-2-/- mice 10-14 weeks old 
were measured by ELISA with a light chain binding plate coat and an isotype 
specific detecting antibody. IgM antibody was nearly 14-fold less in Pim 1-/-2-/- 
animals with 52 ± 15 µg/ml versus 725 ± 173 µg/ml in control mice (p<.01). IgG3 
antibody revealed a similar deficiency as Pim 1-/-2-/- mice had only 88 ± 20 µg/ml 
while control mice measured 734 ± 227 µg/ml (p<.05) (Figure 3.4 A). These 
studies demonstrate a Pim dependent loss of natural antibody.  
In order to confirm the requirement for Pim 1 and 2 for natural antibody 
production, we repeated the serum Ig analysis with Pim 1-/-2-/- and control mice 
backcrossed onto the B6 background. Serum from naïve 14-week-old C57BL/6 
control and Pim 1-/-2-/- mice was assayed for antibody as before. We found that 
the relative antibody in Pim 1-/-2-/- vs. wild type mice for IgM (18.54 ± 2 vs. 738 ± 
199 µg/ml, p<.01), IgG3 (131.2 ± 14 vs. 814.1 ± 101 µg/ml, p<.001), and IgA 
(31.68 ± 4 vs. 87.6 ± 12 µg/ml, p<.001) were significantly reduced (Figure 3.4 B). 
In contrast, the levels of IgG1 and IgE did not differ between Pim 1-/-2-/- and 
control animals. These results were consistent with our previous findings in 
B6x129 mice. 
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To determine which Pim contributed to this defect, we measured the 
serum from single knock out non-immune mice. Both Pim 1-/- and Pim 2-/- had 
significantly decreased IgM serum levels, 55.75 ± 5 µg/ml (p<.01) and 47.27 ± 10 
µg/ml (p<.01) respectively versus 738 ± 199 µg/ml in control mice. IgA levels 
were significantly decreased in Pim 1-/- mice like the Pim 1-/-2-/- mice, 24.68 ± 7 
µg/ml versus 87.6 ± 12 µg/ml in control mice (p<.05) but were normal in Pim 2-/- 
mice (Figure 3.4 B). From this data we concluded that the loss of either Pim 1 or 
2 caused a severe decrease in IgM and the loss of Pim 1 caused the IgA 
antibody to decrease by half. In contrast, Pim 1-/-2-/- mice have normal IgG1 
serum levels while Pim 2-/- mice had significantly higher levels of IgG1.  
The decrease in B1 cells, responsible for production of natural IgM, IgA, 
and some IgG3 antibody, fits with the profile of antibody levels we observed in 
Pim deficient mice. Even though our data indicates that Pim 2-/- mice do not 
contain significantly fewer B1 cells in the peritoneal cavity compared to WT mice, 
there is a large scatter in the data points and the overall average of both B1a and 
B1b cells are in fact closer to that of Pim 1-/-2-/- mice. Keeping this in mind, then it 
is not very surprising that both Pim 1-/- and Pim 2-/- mice have significantly 
impaired IgM levels. 
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Figure 3.4. The loss of Pim 1 and/or 2 impairs natural antibody.  Sera 
collected from naïve Pim 1-/-2-/- and control B6x129 (A) or Pim 1-/-, Pim 2-/-,  
Pim 1-/-2-/-, and control C57BL/6 (B) mice was measured by ELISA for total 
antibody of a specific isotype indicated on the y-axis.  Bars represent SEM, in A 
for IgM n=7, IgG3 n=6, and IgG1 B6 n=4 Pim 1-/-2-/- n=3. In B for each column 
n=5, except IgA where for B6 n=7, Pim 1-/- n=4, and Pim 1-/-2-/- n=12. Statistics 
were determined by student’s t test *=p<.05, **=p<.01, ***=p<.001 
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Peyer’s Patches have diminished B cell numbers 
The main source of IgG3 and IgM antibody in naïve mice are peritoneal B1 
cells, IgA is generated mainly by B1 cells, which have migrated to sites of 
mucosal immunity, primarily in the lung and intestine. Along the intestine are 
Peyer’s patches, organized secondary lymphoid tissues containing B, T, and 
other immune cells that respond to environmental pathogens. Peyer’s patches in 
Pim double mutant mice were visibly smaller but normal in number, however, 
flow cytometry analysis revealed that a germinal center B cells 
(B220+GL7+CD95+) were rare compared to wild type B6 Peyer’s Patches (Figure 
3.5).  
We also determined the absolute number of B cells in the Peyer’s patches 
of WT and Pim deficient mice and found a decrease in the Pim 1-/-2-/- (1.3x106 ± 
.2), Pim 1-/- (.44x106 ± .2), and Pim 2-/- (1.6x106 ± .6) mice compared to WT 
(3.5x106 ± .4). In addition, consistent with our observation that IgA antibody in the 
serum of naive Pim 1-/- and Pim 1-/-2-/- mice was half that of controls, we found 
that the number of IgA+ B cells in Peyer’s patches was decreased with the loss of 
Pim 1. We also found that the IgM+ B cell population in the Peyer’s Patches was 
diminished whether Pim 1 or 2 was lost (Figure 3.6). The diminished IgM+ and 
IgA+ B cells in Peyer’s Patches of Pim 1-/-2-/- mice is consistent with the difference 
observed in the peritoneal B cell cavity most likely because B cells migrate 
between these two areas.  
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Figure 3.5. Peyer’s Patches in Pim 1-/-2-/- mice have significantly fewer GC B 
cells. (A) Cells isolated from Peyer’s patches of control or Pim 1-/-2-/- mice were 
analyzed for the percent of GC B cells (B220+CD95+GL7+). (B) Gating strategy 
for part A. Lines represent the mean and SEM of each group, each symbol 
represents an individual, WT n=10, Pim 1-/- n=2, Pim 2-/- n=3, Pim 1-/-2-/- n=12. 
Statistics were determined by student’s t test *=p<.05, **=p<.01, ***=p<.001 
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Figure 3.6. Peyer’s Patches from Pim 1-/-2-/- mice have diminished B cell 
populations. (A) Peyer’s Patches were isolated from the intestine of WT, Pim 1-/-
, Pim 2-/-, and Pim 1-/-2-/- mice. B cells were identified as B220+ then further 
categorized as IgA+ or IgM+. (B) Gating strategy for part A. Bars represent the 
mean and SEM, each symbol is an individual mouse (n=6). Statistics were 
determined by student’s t test *=p<.05, **=p<.01, ***=p<.001 
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Pim induction after in vitro stimulation of Resting B cells 
The loss of GC and switched B cells in the Peyer’s patches as well as the 
reduction in natural antibody suggests that Pim 1 and 2 kinases are important 
after B cell activation. To assess the induction of Pim kinases after activation and 
determine which pathways may involve Pims, we stimulated B cells in vitro with a 
number of mitogens that engage receptors on the B cell; such as the B cell 
receptor (anti-IgM), anti-CD40, BLyS receptors (BR3, TACI), or toll like receptors 
(LPS, CpG).  
Percoll purified small resting B cells were obtained from GT-GL donor 
mice produced by Dr. Joan Press (Brandeis University) that express a 
immunoglobulin H and L chains specific for the synthetic polypeptide, Poly-L-
(Tyr,Glu)-poly-D,L-Ala--poly-L-Lysine [(T,G)AL] .Using B cells from this double 
knock-in mouse allow us to assess Pim induction when the BCR engaged a 
cognate peptide antigen presenting the dominant (TG)AL epitope, TG4 
(TyrGluGluGluGluTyrTyrGluGluGluGluTyr) conjugated to Ficoll, as well as BLyS, 
anti-CD40, anti-delta-dextran, anti-IgM, CpG and LPS stimulators. The results 
clearly show that stimulation through the BCR, CD40, BR3, TLR4 and TLR9 all 
induced both Pim 1 and Pim 2 with the expected kinetics previously established 
(42, 58) (Figure 3.7). These results demonstrate that the Pim kinases are 
regulated by common B cell stimuli, including activation by a TI-2 cognate 
antigen (TG4). 
 This diverse group of stimuli mimic, as best we can in vitro, activation 
pathways used by TI and TD antigens during B cell activation in vivo. The most 
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direct correlation is stimulation with TG4, a TI-2 antigen, which cross-link BCRs 
to activate the B cell. Using this same pathway anti-IgM and ant-delta-dextran 
also mimic TI-2 activation. However, signaling through the BCR is also a key 
component to TD B cell activation. In vivo the BCR signal requires an additional 
signal through the CD40 receptor, which we have examined alone using anti-
CD40.  Finally, we attempted to copy signaling through the TLRs, which occurs 
during a TI-1 response, by activating the B cells in vitro with CpG and LPS. 
Although each of these pathways can activate NF-kB signaling they also contain 
non-overlapping downstream targets. Whether these divergent pathways result in 
divergent roles for Pim 1 and 2 is discussed in chapter 7.  
In this chapter we have described several impairments in natural and 
mucosal immunity found in naïve mice due to the loss of Pims. Though splenic B 
cell populations are intact, peritoneal B cells are diminished, consistent with the 
decreased sera Ig in these mice. B cells in the Peyer’s Patches were also lower 
in number and had significantly fewer GC B cells suggesting impairment in GC 
formation in Pim 1-/-2-/- mice. These observations are consistent with a role for 
Pim 1 and 2 in activated B cells. Finally, we demonstrated that Pim 1 and 2 are 
induced in vitro under several activation conditions. To our knowledge this is the 
first demonstration of Pim induction after BCR-specific activation, which is 
consistent with a role for Pim 1 and 2 in humoral immunity. Considering these 
results together, we decided to assess whether Pim 1 and 2 kinases are required 
for normal B cell function during an in vivo humoral immune response to antigen.  
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Figure 3.7. Pim kinases are induced upon B cell activation.  B cells isolated 
from GT+ V(D)J knock-in mice were cultured for 12, 24, or 48 hours with 
mitogens indicated.  At each time point protein extracts were made form each 
cell sample and analyzed for induction of Pim 1 or 2 by western blot.  Each Pim 
isoform is labeled, PI3 kinase was used as a loading control.  This blot 
represents 3 separate experiments.  
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Chapter IV 
Thymus Dependent Responses Are Impaired  
By The Loss Of Pim 1 And 2
Introduction 
In a T cell dependent (TD) immune response, B cells are activated 
through T cell help, which facilitates the differentiation and proliferation of antigen 
specific B cells. These cognate activated B cells then proliferate and can develop 
into antibody secreting cells (ASCs) either extrafollicularly, which is generally 
limited to the beginning phase of the response or within a follicle, which is the 
pathway that dominates the response to TD antigens (6, 59). B cells within a 
follicle initiate a germinal center reaction where they can also undergo further 
diversification through isotype switching and affinity maturation (13-15). Isotype 
switching involves the replacement of the Cµ region of the antibody with the 
heavy chain region of another isotype. This does not change the affinity but 
modifies the effector activity of the antibody. The affinity of an antibody can be 
altered by somatic mutations in the variable region of the heavy and light chain, 
this combined with selection for the highest affinity BCR, is a process known as 
affinity maturation. Both of these processes rely on activation-induced cytidine 
deaminase (AID) an enzyme expressed exclusively in B cells about 40 hours 
after activation (16).  
B cells eventually exit the germinal center either as an ASC or a memory 
B cell. How a B cell decides between these two different paths is not completely 
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understood but is likely influenced by the affinity of the BCR and the signal 
strength of other co-stimulatory cascades (59). 
We have demonstrated in the previous chapter that Pim 1 and 2 are 
induced upon B cell activation via the BCR and CD40. Both of these receptors 
play are critical to a B cell’s ability to respond to a TD antigen (59) suggesting 
that Pim 1 and 2 play a role in that response. To measure the affect of the loss of 
Pim 1 and/or 2 on these events, we measured the immune response of Pim 
deficient mice to a TD antigen using several different methods including ELISA, 
ELISpot, immunohistochemistry, and flow cytometry.  
We find that Pim 1-/-2-/- mice display impaired TD antibody to multiple TD 
antigens. This is accompanied by reduced ASCs in the spleen early after 
immunization and in the bone marrow months after immunization, indicating a 
failure to generate and/or sustain long-lived ASCs. Antibody titers in Pim single 
knockout mice were significantly depressed compared to WT but less so than 
Pim 1-/-2-/-. Germinal centers, a hallmark of the response to a TD antigen, were 
also impaired in Pim 1-/-2-/- mice with isotype switching and affinity maturation. 
We further show that adoptively transferred WT antigen specific T cell help 
cannot rescue the response to a TD antigen in Pim 1-/-2-/- mice, demonstrating at 
a minimum a B cell defect. These data point to a critical role for both Pim 1 and 2 
in the response to a TD antigen. 
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Results 
Antigen Specific antibody 
In vitro B cell activation by various mitogens resulted in the induction of 
Pim 1 and 2. If these kinases are important in activated B cells, then it is 
reasonable to think that the humoral immune response in an immunized animal 
may also be affected. In vivo antigen stimulation results in a pool of ASCs 
producing antigen specific antibody, which can be measured in the blood. We 
immunized mice with NP-CGG in alum, a TD antigen, and then examined the NP 
specific antibody response early (day 7 or 10) and late (day 20).  
Our first experiments were performed on B6x129 control and Pim 1-/-2-/- 
mice, which were available from Dr. C. Fox at Jackson Labs. Lambda positive 
antibody specific to NP was 7-fold less in Pim 1-/-2-/- mice with an average of 
131.2 ± 44.9 µg/ml in control mice compared and 18.6 ± 6.4 µg/ml (p<.05) in Pim 
1-/-2-/- mice ten days after immunization. This defect was not due to a delay in 
antibody production, as antibody at 20 days after immunization had not increased 
in Pim 1-/-2-/- mice and continued to be significantly (p<.01) less than controls (7 ± 
.9 vs. 198.1 ± 29 µg/ml) (Figure 4.1 A).  These data indicated that Pim 1 and/or 2 
are critical to a specific humoral response against a TD antigen. We originally 
measured anti-NP λ+ antibody, which does not distinguish between isotypes so 
we next asked if this defect was seen in all isotypes or only, unswitched (IgM) or 
switched (IgG1, IgG3) antibody.  We found that anti-NP IgM+ antibody in  
Pim 1-/-2-/- was 26.8 ± 9.4 µg/ml compared to 71.9 ± 15.7 µg/ml in control mice, 
an almost 3-fold drop (p<.05) ten days after immunization. Twenty days after 
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immunization anti-NP IgM+ antibody in control mice dropped to an average of 
40.7 ± 17 µg/ml, however, the gap widened as Pim 1-/-2-/- mice produced 8-fold 
less with an average of only 4.7 ± 1 µg/ml (p<.05) (Figure 4.1 B).  These same 
serum samples were analyzed for anti-NP specific IgG1+ antibody revealing an 
almost 6.5-fold difference between control and Pim 1-/-2-/- mice at day ten post-
immunization (126.9 ± 38.7 vs. 19.7 ± 8.4 µg/ml, p<.01) as well as a significant 
difference at 20 days post-immunization (245 ± 82 vs. 93 ± 29 µg/ml, p<.05) 
(Figure 4.1 C). Finally, anti-NP IgG3+ antibody was measured 10 days post-
immunization and although titers were low, Pim 1-/-2-/- mice had significantly less 
than controls at day 10 post-immunization (3.8 ± .6 vs. 1.1 ± .2 µg/ml, p<.001) 
(Figure 4.1 D).  The low concentration of IgG3 antibody was not unexpected as it 
is not a dominant isotype in TD responses. We concluded that switched and IgM 
antigen specific antibody was impaired during the response to a TD antigen. 
The response to NP is almost entirely dominated by lambda antibodies.  
Studies on the bone marrow of Pim 2-/- mice have demonstrated a diminution of 
lambda antibodies (60). To ensure that this failure was not specific to NP or due 
to a limited number of lambda positive peripheral B cells, we also immunized 
B6x129 Pim 1-/-2-/- mice with a synthetic polypeptide, Poly-L-(Tyr,Glu)-poly-D,L-
Ala--poly-L-Lysine (T,G)AL, another TD antigen whose response is dominated by 
kappa antibodies. Pim 1-/-2-/- mice still could not mount a TD response to (T,G)AL 
(Figure 4.2).  These results demonstrate a critical role for Pim 1 and/or 2 in the 
generation of antigen specific antibody, independent of antigen or light chain. 
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To pursue this defect in TD antibody further we took advantage of single 
and double Pim knockout mice, which became available backcrossed onto 
C57BL/6 and were again generously provided by Dr. C. Fox. We repeated our 
TD immunization experiments with C57BL/6 control and Pim 1-/-2-/- mice and 
measured antibody at multiple days after immunization.  A significant defect in 
antibody was again observed in Pim 1-/-2-/- mice 7 days (243.4 ± 94 vs. 53.36 ± 
22 µg/ml, p<.05), 10 days (394.7 ± 65 vs. 72.52 ± 18 µg/ml, p<.001), and 14 days 
(692.5 ± 36 vs. 87.18 ± 27.8 µg/ml, p<.001) after immunization. By 20 days after 
immunization antibody in control mice decreased but was still more than 3-fold 
higher than Pim 1-/-2-/- antibody (248.1 ± 66.8 vs. 64 ± 32.5 µg/ml, p<.05). This 
difference continued to thirty days after immunization (302.4 ± 57.9 vs. 104.7 ± 
51.3 µg/ml, p<.05) demonstrating a defect and not delay in the ability of Pim 1-/-2-
/- mice to produce antigen specific antibody (Figure 4.2 A).   
To determine if only Pim 1 or 2 were critical to the humoral immune 
response we immunized C57BL/6 Pim 1-/- and Pim 2-/- single knock out mice with 
50 µg of NP-CGG in Imject alum i.p., these mice were bled every few days to 
monitor antibody to NP. Pim 1-/- mice produced less than half the antibody of 
control mice 7 days after immunization (243.4 ± 94 vs. 108.8 ± 22.9 µg/ml) 
(Figure 4.2 B) while Pim 2-/- mice produce 4-fold less (243.3 ± 94 vs. 49.39 ± 18.9 
µg/ml, p<.05) (Figure 4.2 C). By 14 days after immunization both single knockout 
mice lagged behind at less than one-third of control mice with Pim 1-/- mice 
averaging 219.6 ± 77 µg/ml (p<.001) and Pim 2-/- at 211.5 ± 77.4 µg/ml (p<.001). 
Twenty days after immunization all samples began to decline and single 
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knockout mice were half of controls, both with just over 100 µg/ml while C57BL/6 
mice produce over 200 µg/ml of antibody on average. These numbers stayed 
approximately the same at thirty days after immunization.  Though antibody titers 
in the single knock out mice were a little higher than Pim double knockouts they 
were not significantly different from Pim 1-/-2-/- antibody titers at most time points. 
The exceptions being 10 days after immunization for Pim 2-/- and 14 days after 
immunization for Pim 1-/- mice (Figure 4.2 B&C). These experiments 
demonstrated that the loss of either Pim 1 or 2 results in a defect in antigen 
specific antibody production but the loss of both compounds the defect. 
 We continued our analysis of the C57BL/6 serum by assaying for NP 
specific antibody of different isotypes, as we did with B6x129 mice. Impairment in 
isotype switching would result in a diminution of IgG1 but not IgM antibody. 
Alternatively, a general defect in activation or the production of ASCs would 
result in all isotypes including IgM antibody to be diminished after immunization 
of C57BL/6 Pim 1-/-2-/- mice, as we observed in B6x129 Pim 1-/-2-/- mice.  
Serum from C57BL/6 Pim 1-/-2-/- mice immunized with NP-CGG was 
measured again, this time for NP specific antibody of certain isotypes. We found 
that in Pim 1-/-2-/- and Pim 2-/- but not Pim 1-/- mice, IgM was significantly 
impaired. On day 10, C57BL/6 control mice averaged 654.8 ± 76.5 µg/ml while 
Pim 2-/- and Pim 1-/-2-/- mice were significantly lower with 135.4 ± 24.6 (p<.001) 
and 116.3 ± 54.3 µg/ml (p<.01) respectively.  On day 14 after NP-CGG 
immunization, C57BL/6 control mice averaged 395.7 ± 69.8 µg/ml while Pim 2-/- 
and Pim 1-/-2-/- mice averaged 79.8 ± 26.6 (p<.001) and 52.22 ± 15 (p<.01) µg/ml 
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respectively. This depression in antibody continued to 20 days post immunization 
when control mice averaged 237.2 ± 48.1 µg/ml compared to 55 ± 12.8 µg/ml 
(p<.01) in Pim 2-/- mice and 25.6 ± 11.7 µg/ml (p<.01) in Pim 1-/-2-/- mice. Pim 1-/- 
mice were not significantly different from wild type controls (Figure 4.3 A). From 
this data we conclude that Pim 2 and not Pim 1 is required for normal IgM 
antibody during a TD humoral immune response.   
Now that we know that Pim 1-/- mice have normal, while Pim 2-/- mice have 
diminished IgM antibody titer, we wanted to compare IgG1 antibody (a common 
switched isotype) in the same mice. Samples were measured for IgG1 NP 
specific antibody at 7 and 14 days after immunization. C57BL/6 controls 
averaged 108.3 ± 41.7 µg/ml 7 days after immunization, which was significantly 
more than Pim 1-/-, Pim 2-/-, and Pim 1-/-2-/- averaging 36.9 ± 9.3 (p<.05), 12 ± 3.7 
(p<.05), and 28.3 ± 12 (p<.05) µg/ml respectively. One week later, 14 days after 
immunization, the amount of IgG1 antibody in the WT response had increased as 
expected to an average of 681.1 ± 132 µg/ml. The increase in Pim 1-/- and Pim 2-
/- mice was far less averaging 139.8 ± 37.3 (p<.01) and 26.15 ± 7.5 (p<.01) µg/ml 
on day 14 respectively while IgG1 in the Pim 1-/-2-/- samples decreased to an 
average of 7.1 ± 1.6 (p<.01) µg/ml (Figure 4.3 B). This data extends our previous 
observations by demonstrating that isotype switched as well as IgM antibody is 
impaired in the TD response of Pim 1-/-2-/- and Pim 2-/- mice while only IgG1 
antibody was found to be deficient in Pim 1-/- mice. The loss of IgG1 antibody 
could be caused by a defect in isotype switching. Whereas, the loss of IgM 
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antibody in Pim 1-/-2-/- mice suggests that a generalized defect in B cell 
differentiation or survival also exists.  
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Figure 4.1. Impaired TD responses in B6x129 Pim 1-/-2-/- mice. B6x129 WT or 
Pim 1-/-2-/- mice were immunized i.p. with 50 µg of NP-CGG in Imject Alum. Sera 
was collected at 10 and 20 days after immunization and analyzed for lambda 
(total) (A), IgM (B), IgG1 (C), and IgG3 (D), NP specific antibody. Graphs include 
3 experiments, lines indicate mean and SEM of each group, each symbol 
represents an individual mouse. Red triangles are WT, blue circles are Pim 1-/-2-/-
. Significance was determined by Student’s t test *p<.05, ** p<.01, ***p<.001. For 
WT: unimmunized n=1, Imject Alum only n=3 (IgG3 and IgM) or n=2 (λ and IgG1), 
day 10 n=9 (IgG3 and IgG1), n=8 (IgM), or n=12 (λ), day 20 n=6 (IgG3 and IgM), 
n=5 (IgG1), n=3 (λ); Pim 1-/-2-/- Imject Alum only n=1, day 10 n=9 (IgM, IgG1, and 
IgG3), n=12 (λ), day 20 n=6 (IgG1, IgM, and IgG3) n=3 (λ). 
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Figure 4.2. The Pim 1-/-2-/- antibody deficiency is not specific to one antigen. 
B6x129 control and Pim 1-/-2-/- mice were immunized i.p. with 50 µg of (T,G)AL, 
sera was collected at 7, 14, 21 days after immunization (X-axis) and measured 
for TG4 specific antibody (y-axis). WT n=3 (day 7 and 21) or n= 2 (day 14); Pim 
1-/-2-/- n=1 (day 7) or n=2 (day 14 and 21). Lines indicate mean and SEM of each 
group, each symbol represents an individual mouse. Red triangles are WT, blue 
circles are Pim 1-/-2-/-. Significance was determined by Student’s t test *p<.05, ** 
p<.01, ***p<.001. 
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Figure 4.3. Impaired TD responses in C57BL/6 Pim 1-/-, Pim 2-/-, and  
Pim 1-/-2-/- mice. C57BL/6 WT and Pim 1-/-2-/- (A), Pim 1-/- (B), and Pim 2-/- (C) 
mice were immunized i.p. with 50 µg of NP-CGG in Imject Alum, sera was 
collected at days indicated and measured for anti-NP λ+ antibody. WT and Pim 1-
/-2-/- data includes 4 experiments, Pim 1-/- data is 1 experiment, Pim 2-/- data 
includes 3 experiments. WT day 7 n=3, day 10 n=12, day 14 n=6, day 20 and 30 
n=4, Pim 1-/- day 7 n=5, day 14 n=6, day 20 and 30 n=4, Pim 2-/- day 7 n=4, day 
10 n=11, day 14 n=5, day 20 and 30 n=5, Pim 1-/-2-/- day 7 n=5, day 10 n=13, day 
14 n=6, day 20 and 30 n=4. Lines indicate the mean and SEM, each symbol 
represents an individual mouse, red triangles are WT, blue circles are Pim 1-/-2-/-, 
green inverted triangles are Pim 1-/-, Black boxes are Pim 2-/-, statistical 
significance was determined by student’s t test *p<.05, ** p<.01, ***p<.001. 
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Figure 4.4. Pim 1-/- mice are deficient in IgG1 but not IgM. C57BL/6 control 
and Pim deficient mice were immunized i.p. with 50 µg of NP-CGG in Imject 
Alum, sera were collected at days indicated and measured for IgM (A) and IgG1 
(B) antibody. A includes 2 experiments, WT day 7 n=3, day 10 and 20 n=4, day 
14 n=7, Pim 1-/- day 7 n=5, day 14 n=4, Pim 2-/- day 7 n=4, day 10 and 20 n=5, 
day 14 n=9, Pim 1-/-2-/- day 7 n=5, day 10 n=4, day 14 n=6, day 20 n=3. B 
includes 1 experiment, WT n=3, Pim 1-/- day 7 n=5, day 14 n=4, Pim 2-/- n=4, Pim 
1-/-2-/- day 7 n=5, day 14 n=3. Bars indicate the mean and SEM of each group, 
each symbol represents an individual mouse, red triangles are WT, blue circles 
are Pim 1-/-2-/-, green inverted triangles are Pim 1-/-, Black boxes are Pim 2-/-, 
statistical significance was determined by student’s t test *p<.05, ** p<.01, 
***p<.001. 
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Antigen specific ASC numbers are decreased in Pim 1-/-2-/- 
Whether through the germinal center or the extra-follicular response exposure 
to a TD antigen results in the generation of ASCs. These terminally differentiated 
B cells cease to proliferate and exist to produce antigen specific antibody and will 
do nothing else until they die. A reduced population of antibody secreting cells 
(ASCs) would be consistent with the decrease in antigen specific antibody of 
multiple isotypes we have observed in Pim 1-/-2-/- mice and a role for Pim 1 
and/or 2 in the generation or maintenance of this population. To enumerate the 
number of ASCs in WT and Pim 1-/-2-/- mice we used an antigen specific ELISpot.  
Initial experiments done in B6x129 Pim 1-/-2-/- mice immunized with NP-CGG 
in Imject Alum revealed that ASCs specific to NP in Pim 1-/-2-/- mice were reduced 
2-fold on day 7, 4-fold on day 10, 3-fold on day 14 and 20-fold on day 20 post 
immunization compared to WT (Figure 4.4 A).   
C57BL/6 WT, Pim 1-/-2-/-, and Pim 2-/- mice immunized with NP-CGG were 
sacrificed 10 days after immunization and ASCs were enumerated by ELISpot. 
WT mice averaged 28 ± 7 ASCs/106 splenocytes (n=10), significantly higher than 
Pim 1-/-2-/- mice, which averaged 12 ± 1 ASCs/ 106 splenocytes (n=11). Pim 2-/- 
mice did not produce many more ASCs than Pim 1-/-2-/- at 14 ± 6 ASCs/106 
splenocytes but were not significantly different than WT most likely due to the 
scatter and small number of individuals (n=3) (Figure 4.4 B). These data show 
that consistent with the lower antibody Pim 1-/-2-/- mice have fewer ASCs and 
suggest that Pim 2, at least, is important for normal ASC development after 
immunization with a TD antigen. This decrease in ASCs could be due to a defect 
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in the generation or survival of these cells. This question will be addressed in 
Chapter V.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
83
 
 
 
 
 
 
Figure 4.5. ASC numbers are significantly reduced in Pim 1-/-2-/- mice.  
B6x129 control and Pim 1-/-2-/- mice immunized with 50 µg (T,G)AL absorbed to 
Imject Alum (A) or C57BL/6 control and Pim 1-/-2-/- mice immunized with 50 µg 
NP-CGG absorbed to Imject Alum (B) were sacrificed at days indicated, 
splenocytes were isolated and ASCs were enumerated by ELISpot. (A) Is 1 
experiment, unimmunized and Pim 1-/-2-/- day 7 n=1, WT n=3, Pim 1-/-2-/- day 14 
and 21 n=2 (B) Includes 3 experiments, unimmunized n=5, WT n=11,  
Pim 1-/-2-/- n=10, Pim 2-/- n=3. Bars represent SD, significance was determined 
by student’s t test *p<.05, ** p<.01, ***p<.001. 
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Pim 1 and/or 2 are not absolutely required for germinal center formation 
Antibody secreting cells are generated in a TD response either 
extrafollicularly and/or in a germinal center. Though the number of ASCs in Pim 
1-/-2-/- was significantly decreased, we do not know if this is due to impairment in 
one or both pathways. The presence of germinal centers in splenic follicles is a 
classic hallmark of a TD response. Phenotypic markers can identify B cells 
participating in a germinal center reaction as B220+CD95+GL7+. Flow cytometry 
analysis of splenocytes from B6x129 controls and Pim 1-/-2-/- mice at 7, 10, 14, 
and 21 days post-immunization with NP-CGG or (T,G)AL revealed that in Pim 
deficient individuals, a GC population could not be identified. The number of 
splenocytes counted for each mouse was multiplied by the percent of 
B220+GL7+CD95+ cells found by flow cytometry to determine the number of GC 
B cells per mouse. B6x129 control animals averaged 2x106 ± .5 GC B cells per 
mouse (n=5) at the peak of the response (10-14 days) while GC B cell 
populations in Pim deficient animals remained at background level with .14 ± .07 
GC B cells per mouse (n=4, p<.01). We also observed that naïve Pim 1-/-2-/- mice 
had fewer GC B cells than WT controls. This observation was consistent with 
less Ig in the sera of naïve animals, discussed in the previous chapter. Late in 
the response (3 weeks), B6x129 GC B cell numbers declined as expected but 
remained significantly higher than Pim 1-/-2-/- mice, which also had background 
levels of GC B cells (Figure 4.5 A1). 
 Backcrossed C57BL/6 Pim 1-/-2-/- and control mice were immunized 
with NP-CGG in alum and the same analysis was performed. Again, Pim 1-/-2-/- 
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mice had significantly fewer GC B cells than controls. Ten days after 
immunization, WT mice averaged 0.8x106 ± .1 GC B cells per mouse (n=7), 2.8 
times higher than Pim 1-/-2-/- at 0.28x106 ± .06 GC B cells per mouse (n=9). At 15 
days after immunization that gap increased to 3.7 times as WT controls averaged 
.93x106 ± .9 GC B cells per mouse (n=4) and Pim 1-/-2-/- mice averaged .25x106 ± 
.03 GC B cells per mouse (n=5). Pim 2-/- mice did not differ from WT controls, 
suggesting that Pim 1 is responsible for the defect in germinal center B cell 
numbers (Figure 4.5 A2). This can be tested directly in the future by analyzing 
GCs in Pim 1-/- mice immunized with NP-CGG. We found that Pim 1-/-2-/- mice on 
both the B6x129 and C57BL/6 background generate significantly reduced GC B 
cell populations following a TD immunization. 
 We also looked for germinal center reactions in the spleen by 
immunohistochemistry. Spleen sections from WT or Pim 1-/-2-/- as well as 
unimmunized control mice were fixed and stained with biotinylated peanut 
agglutinin (PNA-biotin), a lectin that identifies germinal centers by binding to a 
certain carbohydrate sequence and can be detected by an enzymatic reaction 
following SA-HRP binding. Counting the number of germinal centers visible in 
spleen sections revealed that in both the B6x129 mixed and C57BL/6 
background Pim 1-/-2-/- had significantly fewer germinal centers visible in the 
spleen (Figure 4.5 B1). This was consistent with our flow cytometry data on 
germinal center B cells for the same mice. In B6x129 experiments only 2 Pim 1-/-
2-/- mice had germinal center numbers above background. Several Pim 1-/-2-/- 
mice had no PNA positive follicles consistent with the lack of GC B cells 
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observed by flow cytometry. Experiments using C57BL/6 Pim 1-/-2-/- mice and 
controls portrayed the same phenomena though each experiment had an outlier, 
which created more scatter when 4 experiments were compiled than we had 
seen in the B6x129 experiments or in the flow cytometry data. Despite the 
scatter, there was a significant difference in the number of PNA+ germinal 
centers at 10 and 15 days after immunization. Ten days after immunization WT 
controls averaged approximately 16 ± 3 PNA+ GCs per spleen section (n=11) 
while Pim 1-/-2-/- mice averaged half as many with just below 8 ± 2 PNA+ GCs per 
spleen section (n=15). Five days later Pim 1-/-2-/- mice averaged .6 ± .4 PNA+ 
germinal center per spleen section (n=5), well below the background determined 
by WT naïve mice (1.4 ± .9, n=5). WT controls also decreased but by a much 
smaller margin, falling from 16 ± 3 to 12 ± 2 PNA+ germinal centers per spleen 
section (n=4), remaining significantly higher than the Pim 1-/-2-/- mice (p<.01) 
(Figure 4.5 B2). From this data in both backgrounds, we concluded that the 
germinal center reaction is impaired in Pim 1-/-2-/- mice. Where this impairment is 
we cannot determine from these experiments but the number of mice with zero or 
background PNA+ numbers suggests that these mice are unable to initiate 
germinal centers during a TD response.   
Un-published reports from the Cancro lab at the University of Pennsylvania 
who were conducting similar experiments with C57BL/6 Pim 1-/-2-/- mice from the 
same source contradicted our results described above.  In that they found the 
germinal center reaction to be intact in Pim 1-/-2-/- mice after NP-CGG 
immunization. In comparing experimental protocols we found that though we both 
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used NP-CGG from Biosearch, the antigen-alum mixture used for each of our 
experiments was prepared differently.  Our lab absorbed antigen onto pre-mixed 
Imject Alum according to manufacturer’s instructions while the Cancro lab 
performed a precipitation of antigen as described in (61).  Briefly, instead of a 
sterile pre-mixed solution as with our procedure, the protein solution is mixed 
with sodium bicarbonate and aluminum potassium. The precipitate is spun off 
and the protein resuspended. To determine if the different antigen-adjuvant 
preparations influenced the results, I performed 2 experiments using NP-CGG in 
alum precipitated by the Cancro lab to immunize our mice.  Mice given 50 µg of 
NP-CGG in precipitated alum were sacrificed 15 days after immunization. In both 
experiments, the number of germinal center cells in the spleen was determined 
by flow cytometry as described above. These results were similar to our previous 
observations with a significant difference (p<.05) between control and Pim 1-/-2-/- 
germinal center B cells (Figure 4.5 C1). However, we noted that 2 out of the 5 
Pim 1-/-2-/- mice in one experiment and 3 out of the 5 in the other experiment had 
a germinal center population detectable by flow cytometry similar in magnitude to 
the WT controls. This was something we had not observed with our previous 
immunizations. PNA+ germinal centers were measured in one experiment and 
the same 2 Pim 1-/-2-/- mice whose flow cytometry profiles revealed a germinal 
center B cell population also had WT numbers of PNA+ germinal centers by 
immunohistochemistry (Figure 4.5 C2). These results were particularly striking 
because of the separation between these two mice and the three who did not 
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have a germinal center population which suggested that the germinal center 
response in Pim 1-/-2-/- mice was either on or off with nothing in between. 
We hypothesized that the loss of Pim 1 and/or 2 impaired signaling 
downstream of the BCR and CD40 receptor, and as a result Pim 1-/-2-/- mice 
could only initiate a germinal center response if signaling through Pim 
independent pathways were increased.  Increased signaling may be achieved by 
a more antigenic stimulus, such as the precipitated alum instead of the pre-mixed 
Imject Alum. Others have proposed that total signal strength through the BCR, 
CD40, and possibly other environmental cues upon encounter with a TD antigen 
determines a B cell’s fate (59). In addition, it has been shown that although a low 
affinity BCR does not exclude WT cells from participating in a germinal center 
reaction, those with a higher affinity have a competitive advantage, accumulate in 
the GC and survive better (62, 63).  
We demonstrated in the previous chapter that both BCR and CD40 activation 
induces Pim 1 and 2 in vitro. Both of these receptors are activated in the TD 
response. Our data demonstrating a significant decrease in the number of 
germinal center B cells and PNA+ germinal centers in Pim 1-/-2-/- mice over 
several experiments is consistent with a role for Pim downstream of both of these 
receptors. It is important to note that as the strength of the adjuvant or antigen 
increased so did the number of Pim 1-/-2-/- mice producing germinal center 
populations by PNA staining and flow cytometry. So the loss of Pim 1 and 2 does 
not make it impossible for a germinal center response to proceed as normal, but 
clearly impacts the likelihood of its occurrence. In the immunohistochemistry 
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data, Pim 1-/-2-/- mice seem to fall into 2 groups, those at background level, and 
those with normal numbers of PNA+ germinal centers, with nothing in between. 
This suggested to us that there was a threshold which must be reached to switch 
the germinal center program on.  We hypothesized then that Pim 1 or 2 lowers 
the threshold of activation in B cells downstream of CD40 and the BCR. This idea 
is also consistent with our finding that NP specific antibody in Pim 1-/-2-/- mice has 
a higher affinity than B6 early in the response, which we will discuss in a later 
section. 
In addition, Pim 2-/- mice were not impaired in the number of germinal center 
B cells or PNA+ germinal centers, suggesting that Pim 1 alone may be 
responsible for this defect. Limitations in our mouse colony prevented us from 
pursuing this further to date, but testing Pim 1-/- mice in the future would 
determine if Pim 1 is responsible for the germinal center defect or both Pim 1 and 
2 must be lost for the germinal center to be impaired.  
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Figure 4.6. Pim 1 and/or 2 are not absolutely required for the 
germinal center response. A-B. Mice were immunized with NP-CGG absorbed 
to Imject Alum A) B6x129 (1) (WT unim n=3, Pim 1-/-2-/- unim n=1, day 7 WT n=2, 
Pim 1-/-2-/- n=1, day 10-14 WT n=5, Pim 1-/-2-/- n=4, days 20-21 WT n=6,  
Pim 1-/-2-/- n=5) and C57BL/6 (2) (Unimmunized: WT n=4, Pim 2-/- n=1, Pim 1-/-2-/- 
n=5, day 10 WT n=7, Pim 2-/- n=4, Pim 1-/-2-/- n=9, day 15 WT n=4, Pim 1-/-2-/- 
n=5) germinal center B cells were identified as CD95+GL7+B220+ by flow 
cytometry and enumerated B) B6x129 (1) (Unimmunized WT n=2, Pim 1-/-2-/- 
n=1, day 10 WT n=8, Pim 1-/-2-/- n=9, day 20 WT n=3, Pim 1-/-2-/- n=3) and 
C57BL/6 (2) (Unimmunized WT n=5, Pim 1-/-2-/- n=7, day 10 WT n=11, Pim 1-/-2-/- 
n=15, Pim 2-/- n=3) day 14/15 WT n=4, Pim 1-/-2-/- n=5) spleen sections were 
fixed and stained with PNA to identify germinal centers. C. Mice were immunized 
with NP-CGG precipitated in alum 1) germinal center B cells were identified by 
facs and enumerated as in A (Unimmunized n=4, day 15 n=10) 2) PNA+ germinal 
centers were identified as in B (Unimmunized n=2, day 15 n=5). D. Gating 
strategy for identifying splenic GC B cells by flow cytometry. Bars indicate mean 
and SEM, each symbol represents 1 mouse, red triangle are WT, black squares 
are Pim 2-/-, blue circle are Pim 1-/-2-/-. Statistical significance was determined by 
student’s t test *p<.05, ** p<.01, ***p<.001 
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Pim 1-/-2-/- B cells have impaired isotype switching 
An activated B cell in the germinal center is often induced by its 
microenvironment to switch isotype, so the effector function of the expressed 
antibody best fits the type of pathogen that elicits the response. Cultured B cells 
can be induced to switch to specific isotypes by engaging different ligands and 
using different cytokine cocktails. After observing a significant decrease in NP 
specific IgG1 antibody in Pim 1-/-2-/- mice, we asked if Pim 1 and 2 also played a 
role in isotype switching in B cells. B cells isolated from WT or Pim 1-/-2-/- mice 
were cultured with different cytokine cocktails (as described in materials and 
methods and the figure legend), to induce switching to a specific isotype. The 
percent of switched isotype B cells was determined by flow cytometry. An 
example of this data can be seen in figure 4.7 where CFSE is measured on the 
x-axis and switching to either IgG1 or IgG2a is measured on the y-axis. 
Proliferation was also examined and determined to be normal. Due to the 
variability found in individuals as well as in separate experiments, the data is 
analyzed as percent of switched B cells in Pim deficient animals divided by the 
percent of switched B cells in WT cultures of the same experiment, resulting in 
the “percent of WT” charted for each culture condition in figure 4.8.  Experiments 
using Pim 1-/-2-/- B6x129 mice revealed that the loss of Pim 1 and 2 impaired 
switching to every isotype tested (Figure 4.8 A). This was consistent with our in 
vivo observations that anti-NP IgG1 and IgG3 antibody was diminished in Pim 1-/-
2-/- mice. We also observed that switching to IgG1 was more severely impaired in 
the anti-CD40 cultures than the LPS cultures (Figure 4.8 A). Encouraged by 
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these results, we repeated the experiments using Pim 1-/-2-/- C57BL/6 mice. 
Again, switching by Pim 1-/-2-/- B cells to each isotype was impaired. Though 
scatter was larger in the B6 Pim 1-/-2-/- samples induced to switch to IgA, 
preventing a significant difference, the mean was only 50% of WT indicating an 
impairment as was observed in B6x129 Pim 1-/-2-/- mice. The same phenomenon 
was observed with regard to IgG1, as B cells cultured with anti-CD40 showed a 
more severe impairment than those cultured with LPS suggesting varying 
dependency on Pims downstream of these receptors. In these experiments, we 
used additional conditions for switching to IgG2a and IgG3. The impairment in 
switching to IgG2a was more severe in cultures given anti-CD40 rather than LPS, 
consistent with results for IgG1. With IgG3, however, both cultures conditions 
(anti-delta-dextran or LPS) resulted a similar level of deficiency (Figure 4.8 B). 
These data indicate that Pim 1 and/or 2 are required for efficient induction of 
isotype switching in a B cell intrinsic mechanism. 
To investigate whether Pim 1 or 2 is required for effective isotype 
switching, we examined Pim single knockout mice. Pim 1 showed a similar 
pattern and magnitude of impairment for all isotypes tested, consistent with this 
being the key kinase (Figure 4.8 C). The results are too limited to draw a 
significant conclusion, however, there was very limited impairment seen in the 
Pim 2-/- (Figure 4.8 D). The only severe impairment seen in the Pim 2-/- mouse 
was switching to IgG1 under conditions with anti-CD40, not LPS. This suggests 
that switching in the Pim 1-/-2-/- B cells under this condition may be worse than 
switching to IgG1 when stimulated with LPS because both Pims are important 
96
downstream of anti-CD40 but not LPS for isotype switching. More experiments 
are needed to pursue this hypothesis. 
 In order for isotype switching to occur, the constant (C) region of the 
targeted heavy chain segment must be accessible. It is thought that which C 
region is accessible, and therefore which isotype the B cell will switch to, is 
controlled by signal cascades downstream of receptors activated by cytokines in 
the B cell’s microenvironment (64). One explanation for the impaired isotype 
switching we have observed is that the C region is not accessible. Accessibility is 
indicated by the presence of sterile transcripts, therefore if the C region is not 
accessible, we would expect RNA sterile transcripts to be decreased. Dr. 
Madelyn Schmidt in our lab isolated RNA from cultures of B cells undergoing 
switching with anti-CD40+IL4 for IgG1 and LPS + anti-delta-dextran then 
measured the sterile transcripts representing one of the most impaired switching 
condition in the C57BL/6 background, IgG2a with CD40 by semi-quantitative PCR 
(Figure 4.9). IgG2a sterile transcripts were unaffected in Pim 1-/-2-/- samples so 
neither Pim 1 or 2 are involved in the accessibility of the C region. Isotype 
switching also relies on the induction of AID. To test whether AID mRNA levels 
were affected by the loss of Pim 1 and 2, Lyn again used the RNA samples from 
B cells induced to switch to IgG2a in culture and measured AID mRNA by semi-
quantitative PCR. Pim 1-/-2-/- and control mice expressed comparable levels of 
AID mRNA (Figure 4.9). So although the loss of Pim 1 and 2 impairs isotype 
switching it is not by limiting accessibility to the C region or decreased expression 
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of AID mRNA. This does not exclude the possibility that the quantity AID protein 
is abnormal, or that Pim 1 or 2 affects the function of AID post-translationally.  
In fact, a number of AID co-factors have been implicated in CSR though 
biochemical evidence is scarce (65). The aberration of any one of these 
components due to the loss of Pim 1 and 2 may be responsible for the decrease 
in isotype switching we have observed. However, because AID is unquestionably 
required for both isotype switching and affinity maturation, which is also impaired 
in Pim 1-/-2-/- mice (described below), we have focused our attention there. There 
are several steps AID at which could be impaired. Although AID expression in 
Pim 1-/-2-/- B cells appears at WT levels we have yet to determine where it is 
localized. AID is normally transported to the nucleus after BCR stimulation (which 
also induces Pim 1 and 2) but the mechanisms regulating this transport are not 
fully elucidated and so could involve Pim 1 and/or 2 (65). In addition to 
transcriptional and localization control, post-translational control is critical to AID 
regulation. Phosphorylation at serine and threonine residues regulates AID 
activity and mutations at these residues have been shown to interfere with 
isotype switching and somatic hypermutation, critical to affinity maturation (66). 
Given the requirement for serine/threonine phosphorylation of AID for normal 
isotype switching and somatic hypermutation and the established role for Pim 1 
and 2 as serine/threonine kinases we hypothesized that Pim 1 or 2 kinases 
modify AID protein thereby affecting the level of isotype switching and affinity 
maturation. We are currently pursuing this idea. 
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Figure 4.7. Flow cytometry analysis of isotype switching and proliferation 
in Pim 1-/-2-/- B cell cultures. B cells isolated from Pim 1-/-2-/- or control mice 
were stained with CFSE and cultured for 3 days with LPS+IL4 or LPS+anti-delta 
dextran+interferon gamma to induce isotype switching to IgG1 or IgG2a 
respectively. Cultures were measured by flow cytometry for expression of these 
switched isotypes, proliferation shown by CFSE dilution on the x-axis, IgG1 or 
IgG2a is shown on the y-axis. Numbers in the top right indicate the percent of 
switched B cells within each gate. These plots represent 4 separate experiments; 
switching efficiency for each condition tested is given in figure 4.9. 
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Flow cytometry analysis of isotype switching and proliferation in  
Pim 1-/-2-/- B cell cultures 
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Figure 4.8. Pim 1-/-2-/- B cells have impaired isotype switching. B cells 
isolated from B6x129 (n=4)(A) or C57BL/6 (n=4) (B) WT and Pim 1-/-2-/- mice, 
Pim 1-/- (n=2) (C), or Pim 2-/- (n=1) (D) were cultured with on of the following 
cocktails; LPS+IL4+BLyS (IgG1, red triangles), anti-CD40+IL4+BLyS (IgG1, green 
circles), LPS+IL4+IL5+TGFβ+BLyS (IgA, open red squares), anti-
CD40+IL4+IL5+TGFβ (IgA, open blue triangles), LPS+INFγ+BLyS (IgG2a, blue 
squares), anti-CD40+INFγ+BLyS (IgG2a, black asterisks), LPS+TGFβ+BLyS 
(IgG2b, green diamonds), LPS+anti-δ-dextran+BLyS (IgG3, inverted purple 
triangles), or LPS (IgG3, black X’s) to switch to isotypes indicated in parenthesis 
and on the Y-axis. A-C includes 2 experiments, D is 1 experiment, lines indicate 
mean and SEM, each symbol above one isotype represents cells isolated from 
an individual mouse.  
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Figure 4.9. Sterile transcripts and AID induction are unaffected in Pim 1-/-2-/- 
B cells. cDNA was made from 1 µg of RNA isolated from B cells of indicated 
genotypes. These B cells had been cultured under conditions conducive to 
switching specifically to IgG2a. Semi-quantitative PCR was used to measure 
IgG2a sterile transcripts (top row) and AID expression (center row). Hprt was used 
as a loading control. Blot is representative of 2 separate experiments. 
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Affinity maturation is impaired in Pim 1-/-2-/- mice 
In addition to isotype switching, the germinal center is the location of affinity 
maturation. Affinity maturation results in higher affinity antibody late in the 
immune response and in a memory response and occurs through two 
mechanisms.  The first is somatic hyper mutation; a high rate of random 
mutations in the variable region alters the binding affinity of the BCR to the 
antigen.  Second, antigen selection means that B cells compete with each other 
in binding antigen, such that those that bind with the greatest affinity continue to 
proliferate and therefore out compete those B cells with a lower affinity BCRs.  
Rounds of mutation and selection result in higher affinity antibody to the antigen.  
Affinity of the BCR has been linked to whether the B cell eventually becomes a 
long-lived plasma cell or a memory cell (59), ensuring that a secondary response 
to the antigen has a higher affinity than the initial response. To investigate the 
ability of Pim 1-/-2-/- mice to undergo affinity maturation, we employed a NP 
specific ELISA using 2 NP-BSA plate coats that had different substitution ratios 
of hapten. NP4-BSA will bind only the high affinity antibody whereas NP14 will 
bind both high and low affinity NP antibody.  Each sample was run on both plates 
and the ratio of high affinity to total antibody detected.  The closer this ratio is to 1 
the higher the antibody affinity in that sample. 
Sera from previous experiments immunizing WT and Pim 1-/-2-/- mice with NP-
CGG in alum were assayed again on each plate coat to determine the antibody 
affinity at various days after immunization. Early in the response WT samples 
averaged a ratio of 0.3 ± .04 indicating low affinity antibody, which is expected. 
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Pim 1-/-2-/- samples, however, were significantly higher than controls averaging 
over .44 ± .03. Pim 2-/- mice were also measured during one experiment and 
were very similar to Pim 1-/-2-/-, averaging .5 ± .07, significantly higher than 
controls 10 days after immunization. The same results for WT and Pim 1-/-2-/- 
mice were obtained 12 days after immunization. As expected, the affinity of 
antibody from control mice increased throughout the duration of the response. 
This is first apparent at 15 days after immunization when the mean affinity of 
control samples was .58 ± .1 and the difference between control and Pim 2-/- or 
Pim 1-/-2-/- samples disappeared. Twenty days after immunization a significant 
difference between control and Pim 1-/-2-/- samples reappeared, this time 
because the affinity of control samples was higher than that of Pim 1-/-2-/- 
samples, .8 ± .03 versus .5 ± .05 respectively. Finally more than 6 months after 
immunization mean affinity continued to climb in control mice while Pim 1-/-2-/- 
mice averaged 0.5 at 15 days, 20 days, and 6 months post immunization (Figure 
4.10). These experiments led to 2 interesting observations. The first is that Pim 1-
/-2-/- affinity was initially higher than controls. The most likely explanation for this 
is that only the high affinity B cells are becoming activated in Pim 1-/-2-/- mice. 
This also fits with our germinal center data described above, where the initiation 
of a germinal center becomes more likely as the immunogen gets stronger. If a 
Pim deficient B cell has a higher activation threshold than its WT counterparts, a 
higher affinity BCR could deliver the increased signal strength needed to push it 
past the threshold. This sub-population of B cells activated in the Pim 1-/-2-/- mice 
would produce higher affinity antibody than controls early in the response.  
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The second observation was that the affinity of Pim 1-/-2-/- antibody did not 
improve over the course of the response so Pim 1 and/or 2 may be involved in 
affinity maturation. This could be an intrinsic B cell defect as we have shown with 
isotype switching. Both processes rely on AID, so a necessary post-translational 
modification dependent on Pim could be responsible for both defects. The other 
possibility is that we are not seeing affinity maturation in the Pim 1-/-2-/- mice 
because the germinal center reaction is impaired. During a TD response affinity 
maturation is thought to occur in the germinal center and may be impaired simply 
due to the decrease in germinal centers in Pim 1-/-2-/- mice.  
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Figure 4.10. Affinity maturation is impaired in Pim 1-/-2-/- mice. WT, Pim 2-/- 
and Pim 1-/-2-/- mice were immunized with 50 µg NP-CGG absorbed to Imject 
Alum, sera was collected at days indicated and affinity was determined by 
measuring the ratio of anti-NP λ+ antibody in each sample binding to a NP-BSA 
plate coat with a low (NP4) and high (NP14) substitution ratio. Graph includes 5 
experiments, lines indicate the mean and SEM of each group, each symbol is an 
individual mouse. Day 10, WT n=18, Pim 2-/- n=5, Pim 1-/-2-/- n=17, day 12 n=4, 
day 15 WT n=8, Pim 2-/- n=4, Pim 1-/-2-/- n=9, day 20 n=6, 6 months n=4.  
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Pim 1-/-2-/- B cells do not respond to secondary challenge 
We have shown that Pim 1-/-2-/- mice immunized with NP-CGG generate 
impaired TD responses. The germinal center reaction can occur but is less 
frequent in Pim deficient mice, possibly due to the ability of an immunogen to 
sufficiently activate Pim 1-/-2-/- B cells. Memory B cells are generated in the 
germinal center and whether an activated B cell becomes a memory B cell is 
thought to be closely linked to its affinity. In normal mice, high affinity memory B 
cells develop from the germinal center and migrate to the bone marrow along 
with antigen specific long lived ASCs. To determine if Pim 1-/-2-/- mice are able to 
respond to a secondary challenge, we immunized Pim deficient and control mice 
with 50 µg NP-CGG absorbed to Imject Alum then transferred B cells from these 
mice mixed with T cells from KLH primed B6 mice into irradiated B6 recipients. 
WT and Pim 1-/-2-/- B cell donors were immunized with 50 µg of NP-CGG in alum 
more than seven months prior to the transfer of memory B cells, T cell donors 
were primed with KLH in alum more than 8 weeks prior to transfer.  
WT B6 mice were exposed to 600 rads the day before the transfer. 
Recipient mice were given 5 or 7 million T cells (varied by experiment) isolated 
from KLH primed WT B6 mice and 2 or 10 million B cells from either WT B6 or 
Pim 1-/-2-/- NP primed mice. 24 hours after transfer recipient mice were 
challenged with 50ug of NP-KLH and bled 10 days later.  An NP specific ELISA 
was used to measure antibody generated in recipient mice.  Mice receiving 2 
million B cells from NP-CGG immunized WT or Pim 1-/-2-/- animals did not mount 
a strong antibody response to NP-KLH. Mice receiving 10 million B cells from WT 
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animals immunized previously with NP-CGG generated an antibody response 
averaging 76.63 ± 15.7 µg/ml (n=7) compared to 3.75 ± 1.9 µg/ml (n=9) by mice 
receiving 10 million Pim 1-/-2-/- B cells (Figure 4.11 B). Mice receiving only WT B 
cells, only T cells, or no antigen were used as controls to determine background 
NP antibody.  
Bone marrow was also taken from the B cell donors and examined by 
ELISpot for NP specific long-lived ASCs. This revealed that Pim 1-/-2-/- mice had 
significantly fewer long lived ASCs in their bone marrow with an average 23 ± 12  
NP+ ASC/mouse compared to 277 NP+ ± 62 ASC/mouse in WT mice (Figure 
4.11 A). 
Our results show a significant defect in the ability of Pim 1-/-2-/- B cells to 
respond to a secondary challenge.  This could reflect the inability of Pim 1-/-2-/- B 
cells to generate memory cells particularly because long-lived ASCs and memory 
B cell are products of the germinal center response, which was impaired in Pim 
1-/-2-/- mice. Alternatively our results could reflect a defect in the ability of an 
intact memory B cell pool to differentiate into antibody secreting cells. 
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Figure 4.11. Pim 1-/-2-/- mice do not respond to a secondary challenge. Mice 
immunized more than 6 months prior with 50 µg NP-CGG absorbed to Imject 
Alum were sacrificed. (A) anti-NP λ+ ASCs in the bone marrow were enumerated 
by ELISpot; Unimmunized n=2, WT n=8, Pim 1-/-2-/- n=9 (B) 2 or 10 million B cells 
were transferred along with KLH primed T cells into irradiated recipient mice who 
were immunized with NP-KLH 24 hours after transfer. Sera was collected at day 
10 and measured for anti-NP λ+ antibody. WT n=7, Pim 1-/-2-/- n=8 (2x106) or 9 
(10x106), B or T cells only n=3, antigen only n=4. Graphs include 2 experiments. 
B or T cells were transferred alone as a control, “no antigen” refers to mice 
receiving 10x106 WT B cells with KLH primed T cells who were not immunized 
with NP-KLH after transfer. Each symbol represents an individual mouse, lines 
represent the mean and SEM. 
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WT T cell help cannot compensate for the loss of Pim 1 and 2 in B cells 
 B cell activation and antibody production in TD responses depends upon T 
cell help. It is therefore possible that the impairment we have observed in the TD 
response is due to T cell defects. To determine whether WT T cell help would 
correct the TD response in Pim 1-/-2-/- mice, we used spleen cells from OT II  
rag2-/- mice, which do not contain any B cells. T cells in these mice are specific to 
OVA, so transferring a small number of these T cells into Pim 1-/-2-/- mice was 
sufficient for T cell help during an immune response to NP-OVA. WT or  
Pim 1-/-2-/- mice receiving 1-2 million OT II splenocytes were immunized with 100 
µg NP-OVA absorbed to Imject Alum and NP specific antibody was measured at 
7 and 14 days after immunizations. A significant difference was observed 
between WT and Pim 1-/-2-/- mice given OT II T cells as early as day 7 as anti-NP 
λ+ antibody in WT mice averaged 352 ± 43 µg/ml versus 54.2 ± 11.96 µg/ml in 
Pim 1-/-2-/- mice (p<.0001). A significant difference was also observed 10 (250.8 ± 
72 µg/ml vs. 51.9 ± 18 µg/ml) and 14 (341.5 ± 64.2 µg/ml vs. 137.7 ± 32.4 µg/ml) 
days after immunization (p<.01). The addition of WT T cell help did not correct 
the deficiency in the TD response in Pim 1-/-2-/- mice indicating that a T cell defect 
is not solely responsible for the TD impairment though we can not rule it out as a 
contributing factor. These data were consistent with the hypothesis that Pim 
deficiency is manifest in B cells impairing a TD response. Experiments in Chapter 
V test this hypothesis.  
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Figure 4.12. WT T cell help does not repair the TD response in Pim 1-/-2-/- 
mice. Unirradiated B6 (red triangles) or Pim 1-/-2-/- (blue circles) mice received 
OT II T cells (specific to OVA) (open symbols) or not (closed symbols) and were 
immunized with 100 µg NP-OVA in Imject alum. Sera was collected and 
measured for anti-NP λ+ antibody at days indicated. Data are pooled from 3 
experiments, lines represent mean and SEM for each group, each symbol is an 
individual mouse. Day 7 no cells n=11, WT OT cells n=12, Pim 1-/-2-/- OT cell 
n=13, day 10 no cells n=8, OT cells n=9, day 14 no cells n=11, OT cells n=7.  
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Chapter V 
Thymus Independent Responses In Pim 1-/-2-/- Mice 
 
Introduction 
 Antigens can be classified as TD or TI based on whether or not they 
required T cell help to elicit an immune response. TI antigens produce an 
immune response without T cell help and can then be further subdivided into TI-1 
or TI-2. The separation of these two categories was originally defined by the lack 
of a TI-2 response generated in CBA/N mice, which have an X-linked immune 
deficient gene, xid, (67, 68). TI antigens have since been defined by their method 
of activating a B cell. TI-1 antigens have intrinsic non-specific B cell activating 
activity, such as LPS, which activates B cells by binding to TLRs. TI-2 antigens 
have repeating epitopes, which cross-link BCRs on the B cell surface, leading to 
activation.   
 Another difference in TI antigens is the observation that they activate 
different B cell subpopulations. TI-1 antigens are characterized by an expansion 
of conventional B2 B cells (6).  The primary site for follicular B2 B cells is the 
spleen and these are found in normal numbers in the spleens of Pim 1-/-2-/- 
knockout mice. The response to TI-2 antigens, however, is controlled largely by 
the MZ and B1 B cell subsets (6, 69). We have already shown that the number of 
Peritoneal B1 B cells is diminished by the loss of Pim 1 or 2, which may affect 
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our TI-2 immunization results in these mice, however, marginal zone B2 cells are 
found in normal number in the spleens of Pim 1-/-2-/- mice.  
Studies indicate that i.p. administration of TI-2 antigen relies primarily on 
peritoneal B cells for a robust response while i.v. administration relies on the 
splenic MZ and Bl a B cell populations (70). For example, i.p. administration of 
the R36A streptococcal vaccine (a TI-2 antigen) to CXCL13-/- mice, which have 
cell migratory defects and diminished numbers of peritoneal B cells, results in a 
significantly reduced antibody response relative to normal controls. In contrast, 
the same vaccine administered i.v. elicits a normal antibody response because 
intravenous delivery to the spleen can activate the intact MZ population (70). 
These experiments indicate that we can use the route of administration of 
antigen to target different populations of B cells.  
Despite the route of immunization, B cells activated by a TI-2 antigen 
differentiate into ASCs. This differentiation involves a tightly regulated specific 
genetic program, which has been partly elucidated.  The most critical ASC 
associated transcription factor is B Lymphocyte induced maturation protein 1 
(BLIMP-1), the loss of which severely impacts ASC generation (17) whereas over 
expression can spontaneously induce ASC differentiation (18). Immunization of 
conditional BLIMP-1 knockout mice resulted in a 3-fold decrease and 10-fold 
decrease in ASCs to both TD and TI-2 antigens, respectively (17).  In vitro, 
BLIMP-1-/- B cells proliferate normally but do not generate ASCs after LPS 
activation. In addition to BLIMP-1, IRF4 has been identified as another key 
transcription factor in ASC differentiation. IRF4 is the first transcription factor t 
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induced upon B cell commitment to the ASC lineage followed by BLIMP-1 
although it is not clear if there is a direct linear relationship between IRF4 and 
BLIMP-1 expression (19, 20). Consistent with its role in ASC development,  
IRF4-/- B cells generate 95% fewer ASCs when activated in vitro and few CD138+ 
B cells after in vivo TD immunization (19, 20). A third transcription factor involved 
in ASC generation is XBP-1 (21). XBP-1 is downstream of IRF4 and BLIMP-1; B 
cells lacking either IRF4 (19) or BLIMP-1 (17) have no induction of XBP-1, 
demonstrating that XBP-1 expression depends on the expression of either IRF4 
and/or BLIMP-1. Although in vitro experiments revealed that survival and 
proliferation were unaffected in XBP-1-/- B cells, in vivo immunization produced 
70-fold fewer ASCs and little IgM and IgG3 response to TI-2 and TD antigens, 
respectively (21). 
Chapter IV of this dissertation investigated the affect of losing Pim 1 and 2 
on a TD immune response. Providing antigen specific WT T cell help before 
immunizing Pim 1-/-2-/- mice with a TD antigen did not improve the response, 
consistent with an intrinsic B cell defect. To more closely examine the B cells, we 
evaluated immune response of Pim 1-/-2-/- mice to TI antigens. We found that the 
loss of Pim 1 or 2 negatively impacts the response to both TI-1 and TI-2 antigens 
and in the case of the TI-2 response even i.v. antigen delivery to Pim 1-/-2-/- to the 
intact MZ B cells does not produce a response. In vitro experiments revealed that 
Pim 1-/-2-/- B cells proliferate and survive normally to TI antigens but generate 
reduced ASC numbers, supporting the notion that differentiation to an ASC was 
blocked. Taking advantage of a mouse model containing a GFP marker for 
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BLIMP-1 expression, a key regulator in ASC development, we were able to 
determine that Pim 1-/-2-/- B cell are unable to induce BLIMP-1 normally, resulting 
in the significant drop in the number of ASCs and antibody.  
 
Results 
Pim 1 or 2 are required for TI-2 responses 
The humoral response against NP-CGG described in the previous chapter 
requires T cell help and the reduced antibody response could be due to a defect 
in the T and/or B cell function. We have shown that addition of wild type T cells 
does not correct the TD defect, consistent with a B cell intrinsic defect. To test 
the ability of Pim 1-/-2-/- B cells to respond in vivo, we immunized control and Pim 
1-/-2-/- mice with NP-Ficoll and TG4-Ficoll, TI-2 antigens that do not require T cell 
help. 
B6x129 Pim 1-/-2-/- and control mice were immunized with 50 µg NP-Ficoll 
in PBS i.p.; lambda positive antibody to NP, the dominant antibody light chain 
used in this response, was measured from serum samples taken at 3-13 days 
post-immunization. Antibody to NP in Pim 1-/-2-/- mice was significantly decreased 
compared to control wild type mice on day 3 (1 ± .2 vs. 10.3 ± 3.6 µg/ml, p<.05), 
day 5 (1.2 ± .4 vs. 44.8 ± 5.2 µg/ml, p<.001), day 7 (2.1 ± 1.1 vs. 210.8 ± 17.3 
µg/ml, p<.001), and day 10 (7.2 ± 4.3 vs. 222.9 ± 44.1, p<.001) after 
immunization (Figure 5.1 A). These data demonstrated that Pim 1-/-2-/- mice were 
unable to respond to a TI-2 antigen, consistent with the idea of an intrinsic B cell 
defect. 
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Further studies using fully backcrossed C57BL/6 Pim1-/-2-/- and control 
mice confirmed our initial findings.  After immunization with NP-Ficoll, total λ+ NP-
specific antibody from Pim 1-/-2-/- mice was lower than B6 mice on all days 
examined (Figure 5.1 C).  By three days after immunization, a 5-fold difference in 
NP specific antibody was observed between Pim 1-/-2-/- and WT mice (2.2 ±1.2 
vs. 10 ± 1.4 µg/ml, p<.001) and by 5 days after immunization the difference 
increased to 11-fold (13.26 ± 2.8 vs. 145.9 ± 20.3 µg/ml, p<.001). The greater 
than 10-fold antibody levels between Pim 1-/-2-/- and WT responses to NP-Ficoll 
continued through out the response; 10-fold at day 7 (20.8 ± 4.3 vs. 206.7 ± 19.7 
µg/ml, p<.001), 14-fold at day 10 (18.85 ± 3.6 vs. 270 ± 33.9 µg/ml, p<.001), and 
25-fold at day 13 (16.17 ± 2.5 vs. 410.2 ± 44.6 µg/ml, p<.001). We looked at 
longer times post-immunization to assess whether the Pim 1-/-2-/- response was 
just delayed, however, the NP specific antibody did not increase to wild type 
levels. These results are consistent with a B cell intrinsic functional defect in Pim 
1-/-2-/- mice. 
To assess the role of the individual Pim kinases in the TI-2 response, we 
immunized single knockout mice with 50 µg of NP-Ficoll in saline i.p..  
Responses of Pim 1-/- mice immunized with NP-Ficoll were similar to that of B6 
mice up until day 10 (250 ± 68 µg/ml vs. 270 ± 33.9 µg/ml) following 
immunization (Figure 5.1 B).  By day 13, however, the response of Pim 1-/- mice 
had declined to below 200 ± 12 µg/ml (p<.01) whereas B6 levels continued to 
increase suggesting that Pim 1 is important for the maintenance of the TI-2 
response. Pim 2-/- mice also responded to NP-Ficoll and their response 
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displayed delayed kinetics and a reduced magnitude relative to B6 controls at 
each time point. Therefore single knockouts respond to challenge with NP-Ficoll 
with altered duration or magnitude of antibody production suggesting separate 
roles for Pim 1 and 2 during the TI-2 response. These individual mutations 
synergize to ablate the response to TI-2 antigen in the double knockout.  
Pim 2 deficiency has been shown to result in decreased numbers of λ+ 
light chain B cells in bone marrow populations (60).  Because the bulk of the 
NP-response is produced by λ+ B cells, deficiencies in the development of this 
population might account for the lower response to NP-Ficoll we observed.  We 
assessed this possibility by immunizing with two other TI-2 antigens whose 
response is not dominated by the λ light chain, TG4-Ficoll and TNP-Ficoll and 
then measuring the κ+ specific response. B6x129 control and Pim 1-/-2-/- mice 
were immunized with 50 µg of TG4-Ficoll. At the peak of the response (day 5) 
the mean antibody titer from WT mice was 51.1 ± 12.4 µg/ml and Pim 1-/-2-/- 
mice was 4.4 ± 1.2 µg/ml (p<.01), which was not above the unimmunized 
background (Figure 5.1 C). Although the antibody titer in WT mice had declined 
by 10 days (23.9 ± 4.6 mg/ml) after immunization it was still significantly higher 
than Pim 1-/-2-/- mice, which had not increased relative to day 5 (5.2 ± 1.5 µg/ml, 
p<.01). The response to TNP-Ficoll by Pim 1-/-2-/- mice was reduced about 3.5-
fold compared to B6 mice on both days (p<.001) (Figure 5.1 D).  Pim 1-/- sera 
averaged 142.4 ± 32 µg/ml at 5 days (p<.05) and 96.75 ± 11.6 µg/ml at 10 days 
(p<.001) after TNP-Ficoll immunization, significantly less than WT on both days. 
Sera from Pim 2-/- was significantly less than WT mice averaging 138.6 ± 23.2 
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µg/ml (p<.05) 5 days after immunization, however, by 10 days after 
immunization the mean anti-TNP antibody in WT decreased enough that Pim 2-/- 
sera was no longer significantly different.  TNP specific antibody levels in Pim 2-
/- mice did not differ significantly from day 5 to day 10. Thus responses to all 3 
TI-2 antigens were depressed in Pim 1-/-2-/- mice, demonstrating that this 
phenomenon is not specific to NP or the result of a diminished lambda+ B cell 
population.  
The number of NP specific ASCs was also measured by ELISpot. For 
B6x129 mice immunized with NP-Ficoll, Pim 1-/-2-/- had over 10-fold fewer ASCs 
on day 3 (127.4 ± 50 vs. 1416 ± 49.8 ASCs/106 splenocytes, p<.001) and 20-
fold fewer on day 7 (54.3 ± 25 vs. 1112 ± 185 ASCs/106 splenocytes, p<.01) 
compared to WT (Figure 5.2 A). NP specific ASCs in C57BL/6 Pim 1-/-2-/- mice 
were also decreased significantly compared to B6 controls at day 5 (16.47 ± 2.8 
vs. 49.44 ± 11.7 ASCs/106 splenocytes, p<.05) and day 10 (8.4 ± 2.8 vs. 48.4 ± 
14.7 ASCs/106 splenocytes, p<.05) (Figure 5.2 B). Although each ELISpot can 
vary based upon differences between individual mice, incubation times, and 
counting, the difference observed between the scales of parts A and B of figure 
are due to optimization of the ELISpot assay over time. Note that the 
background is far less in part B than in part A.  
A diminution in splenic ASCs during the immune response is not 
unexpected. Considering the significant decrease in antibody observed during 
the short time of the TI-2 response, we asked whether this ASC defect extended 
to the long-lived ASC population by aging mice immunized with NP-Ficoll. More 
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than 6 months after the NP-Ficoll immunization mice were sacrificed and NP-
specific λ+ ASCs in the spleen were enumerated by ELISpot. ASCs in Pim 1-/-2-/- 
mice were 3.5-fold lower compared to WT (6.2 ± 1.1 vs. 21.8 ± 4.2 ASCs/106 
splenocytes, p<.05) while the mean ASCs in Pim 1-/- mice was a little more than 
half of WT (13.26 ± 2.2 vs. 21.8 ± 4.2 ASCs/106 splenocytes) this was not a 
statistically significant difference (Figure 5.2 C). Long-lived ASCs in the bone 
marrow after a TI immunization have been reported by some groups but not 
others. We measured bone marrow samples from these mice as well but did not 
detect any NP specific ASCs. These data reveal a defect in ASCs associated 
with the most severe antibody defect found in Pim 1-/-2-/- mice.   
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Figure 5.1 Pim 1-/-2-/- mice do not respond to TI-2 antigens. (A) B6x129 Pim 1-
/-2-/- and control mice were immunized i.p. with 50 µg of NP-Ficoll; sera was 
measured for anti-NP λ+ antibody at days indicated. Data includes 2 experiments 
WT: day 3 n=5, day 5 n=6, day 7 n=3, day 10 n=9 Pim 1-/-2-/-: day 3 n=6, day 5 
n=5, day 7 n=3, day 10 n=9.  (B) C57BL/6 Pim deficient and control mice were 
immunized i.p. with 50 µg NP-Ficoll, mean anti-NP λ+ antibody is given for each 
time point over 3 experiments, bars represent SEM, For days 3 and 7: WT n=8, 
Pim 1-/- n=6, Pim 2-/- n=7, Pim 1-/-2-/- n=10, for day 5 WT n=12, Pim 1-/- n=6, Pim 
2-/- n=12, Pim 1-/-2-/- n=16, for day 10 WT n=16, Pim 1-/- n=6, Pim 2-/- n=17, Pim 1-
/-2-/- n=20, for day 13 WT n=4, Pim 1-/- n=4, Pim 2-/- n=7, Pim 1-/-2-/- n=3. (C) 
B6x129 Pim 1-/-2-/- and control mice were immunized i.p. with 50 µg TG4-Ficoll, 
sera was measured for anti-TG4 F(ab)2+ antibody at days indicated, graph 
includes 2 experiments, lines indicate mean and SEM, WT/Pim 1-/-2-/- unim n=2 
at days 5 and 10 n=6. (D) C57BL/6 mice of indicated genotypes were immunized 
i.p. with 50 µg of TNP-Ficoll, anti-TNP F(ab)2+ antibody was measured on days 5 
and 10. Graph includes 1 experiment, for day 5 WT n=6, for day 10 WT n=5, on 
both days Pim 1-/- n=4, Pim 2-/- n=4, Pim 1-/-2-/- n=5. For A, C, and D each symbol 
represents an individual mouse. Statistics were determined by student’s t test 
*=p<.05, **=p<.01, ***=p<.001. In all experiments unimmunized background sera 
was below 20 µg/ml. 
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Pim 1-/-2-/- mice do not respond to TI-2 antigens 
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Figure 5.2. Pim 1-/-2-/- mice have reduced ASCs after immunization with NP-
Ficoll. ASCs in the spleen of B6x129 (A) or B6 (B) control and Pim deficient mice 
were enumerated by ELISpot at days indicated after i.p. immunization with 50 µg 
of NP-Ficoll. (A, n=3) (B, n=5) C. ELISpots were performed on spleen samples 
from some mice in Figure 5.1 part B >6 months after immunization with NP-Ficoll. 
WT n=4, Pim 1-/- n=6, Pim 1-/-2-/- n=4. Unimmunized WT splenocytes were used 
as a background control. Background on part C was zero. ELISpot was 
performed with an NP-BSA plate coat and anti-mouse λ detecting antibody. 
Statistics were determined by student’s t test *=p<.05, **=p<.01, ***=p<.001 
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Splenic B cells do not respond to TI2 antigen in Pim 1-/-2-/- mice 
There is evidence in the literature that i.p. administration of an antigen 
relies primarily on peritoneal B cells for a robust response whereas i.v. 
administration relies on the splenic MZ and Bla B cell populations. In CXCL13-/- 
mice, which have cell migration defects (70), i.p. administration of the R36A 
streptococcal vaccine (a TI-2 antigen) results in a significantly reduced antibody 
response relative to normal controls. In contrast the same vaccine administered 
i.v. produces a normal robust response. This occurs because intravenous 
delivery activates the intact and functioning MZ population while an i.p. injection 
relies on B1 B cells in the peritoneal cavity, which are diminished in CXCL13-/- 
mice due to the migratory defect (70). We wanted to eliminate the possibility that 
the decreased response to TI-2 antigen was due to the diminution of peritoneal 
B cells and not a functional defect in the splenic B cells. Pim 1-/-2-/- and B6 mice 
were immunized with 50 µg of NP-Ficoll in PBS by i.p. or i.v. routes then bled 5, 
7, and 10 days post immunization.  Although the TI-2 response was more robust 
when B6 mice were immunized i.v., Pim 1-/- 2-/- mice did not show an improved 
response to NP-Ficoll (Figure 5.3 A). Pim 1-/- and Pim 2-/- mice showed a 
divergent antibody response from Pim 1-/-2-/- when immunized i.p with NP-Ficoll  
(Figure 5.1). To determine if a defect in the B1 B cell population could be 
responsible for the impaired TI-2 responses in Pim single knockout mice, we 
immunized control and Pim deficient mice with 50 µg NP-Ficoll i.v. and 
monitored the antibody response. Both Pim 1-/- and Pim 2-/- displayed normal TI-
2 antibody titers after i.v. immunization (Figure 5.3 B) supporting our notion that 
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the defect observed with i.p. immunization was due to the diminution of B1 B 
cells in the peritoneal cavity and not due to an inability in Pim single knock-out B 
cells to response to TI-2 antigens. Pim 1-/-2-/- mice continued to generate a 
significantly impaired TI-2 response (p<.05, Figure 5.3 B) when antigen is 
delivered i.v. directly to the intact MZ population so we conclude that a migratory 
or developmental defect of the B1 B cells is not responsible for the loss of the 
TI-2 response in Pim 1-/-2-/- mice.  
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Figure 5.3 Pim 1-/-2-/- MZ B cells do not respond to TI-2 antigen. C57BL/6 
mice of indicated genotypes were immunized with 50 µg NP-Ficoll, sera was 
collected at indicated time points and measured by ELISA for anti-NP λ+ 
antibody. Each symbol represents an individual mouse, lines indicate the mean 
with SEM, statistics were determined by student’s t test *=p<.05, **=p<.01, 
***=p<.001. (A) I.p. and i.v. immunizations were compared (B) I.v immunization 
among the 4 genotypes.  
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Pim 1-/-2-/- MZ B cells do not respond to TI2 antigen 
 
A.  
0
100
200
300
400
500
600
700
800
900
1000
1100
5 7 10
WT IV
Pim 1-/-2-/- IV
Pim 1-/-2-/- IP
WT IP
*
*
**
*
*
 
B. 
0
100
200
300
400
500
600
700
800
5 7 10 13
WT
Pim 1-/-
Pim 2-/-
Pim 1-/-2-/-
*
*
*
*
*
 
 
 
 
133
TI-1 responses are deficient in Pim 1-/-2-/- mice 
Our TI-2 results above are consistent with a response defect in MZ B 
cells, which are normal in number and location in Pim 1-/-2-/- mice. TI-1 antigens 
also activate B cells without T cell help but are characterized by an expansion of 
conventional follicular B2 B cells not MZ B cells (6). As shown in chapter III, 
follicular B cells are also normal in proportion and number in Pim 1-/-2-/- mice 
(Figure 3.1). To determine if impaired antibody responses also extended to TI-1 
antigens, we immunized Pim 1-/-2-/- and B6 mice i.p. with 25 µg of FITC-LPS.  
FITC specific antibody was measured by ELISA. TI-1 responses were 
significantly impaired in Pim 1 and 2 deficient mice relative to B6 controls on 
days 5 and 10 post immunization (Figure 5.4).  The mean antibody in Pim 1-/-2-/- 
mice was found to be 10 fold less than that in B6 mice (5 ± 1.5 vs. 60.5 ± 11.7 
µg/ml, p<.001) on day 5 and 6-fold less on day 10 as Pim 1-/-2-/- anti-Fitc antibody 
remained the same 5 ± 1.9 µg/ml but decreased in WT to 29.5 ± 4.1 µg/ml 
(p<.001). We examined single knockout mice to determine if this phenotype 
could be attributed to the loss of a particular Pim kinase.  At day 5 post-
immunization anti-FITC antibody levels in Pim 1-/- mice were below 20 µg/ml, less 
than one-third the average in B6 mice.  It is also noteworthy that while the 
response of Pim 1-/- mice was reduced relative to control mice, their antibody 
response was significantly higher than that of Pim 1-/-2-/- mice (p<.01). The mean 
antibody level in Pim 2-/- mice was found to be 8 ± 5.3 µg/ml approximately one-
tenth that of the response of control mice (p<.001) (Figure 5.4). Ten days after 
immunization Fitc specific antibody in both Pim 1 and Pim 2 knock out mice did 
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not change from day 5 at 17 ± 3.1 µg/ml and 9 ± 1.2 µg/ml, respectively. These 
data indicate that the loss of Pim 1 has a more modest affect on the TI-1 immune 
response than Pim 2. Taken together, these results confirm a B cell intrinsic 
defect for Pim 1-/-2-/- mice and show distinctions in Pim control of the TI-1 and TI-
2 responses. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
135
 
 
 
 
 
 
 
Figure 5.4. The loss of Pim 1 or 2 impairs TI-1 responses. Mice of indicated 
genotypes were immunized i.p. with 25 µg of Fitc-LPS. Sera was measured for 
anti-Fitc F(ab)2+ antibody at 5 and 10 days after immunization. Each symbol 
represents an individual mouse, lines indicate the mean and SEM, Wt n=9, Pim 
1-/- n=8, on day 5 Pim 2-/- n=10 and Pim 1-/-2-/- n=11, on day 10 Pim 2-/- n=9, and 
Pim 1-/-2-/- n=10. Statistics were determined by student’s t test *=p<.05, **=p<.01, 
***=p<.001.  
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Despite normal activation and proliferation in vitro ASC generation is 
impaired in Pim 1-/-2-/- B cells  
The defects observed in antibody generated in vivo to TD and TI antigens 
as well as the amount of natural antibody in unimmunized mice pointed to an 
underlying deficiency in antibody production. Consistent with the antibody 
analysis, ELISpot results revealed significantly fewer ASCs in Pim 1-/-2-/- mice 
after immunization with a TD or TI-2 antigen. The diminished number of ASCs 
could be due to a defect in differentiation of B cells into ASCs or survival of these 
cells once they were generated.  
First we determined if Pim 1-/-2-/- B cells were becoming activated when 
they encountered a mitogen in vitro. B cells isolated from Pim 1-/-2-/- or control 
mice were cultured with the mitogens LPS, anti-IgM and anti-CD40 for 24 or 48 
hours then analyzed by flow cytometry for surface expression of early activation 
markers. Pim 1-/-2-/- cultures displayed equivalent induction of activation markers 
CD69, CD71, and CD95 as wild type, indicating that early signaling events in 
these 3 pathways were intact (Figure 5.5). To examine ASC differentiation more 
closely, we used an in vitro system to generate ASCs by culturing purified B cells 
for 4 days with LPS.  This system allows us to compare Pim 1-/-2-/- to B6 control B 
cells in survival, proliferation, and the generation of ASCs. After 4 days in culture 
cell counts and proliferation were comparable (Figure 5.6 A/B). Equivalent 
numbers of viable cells coming out of culture and rounds of proliferation are 
strong evidence that survival is not compromised by the loss of Pim 1 and 2; 
however, it could be difficult to detect a survival difference within the small 
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subpopulation of ASCs that are produced. To definitively look at cell survival 
within the ASC population, we would need a marker to identify ASCs among 
other cells in the culture. This will be addressed in the next section.  
Differentiation into ASCs in these cultures was determined by ELISpot and 
revealed a significant deficiency in Pim 1-/-2-/- mice, which generated only one-
third the number of ASCs as control mice (Figure 5.6 C). Loss of either Pim 1 or 
2 alone did not reduce ASC generation. The loss of IRF4 negatively impacts ASC 
generation (19, 20). To compare the defective ASC generation between IRF4-/- 
and Pim 1-/-2-/- mice, B cells were isolated from spleens (IRF4-/- generously 
provided by Dr. Ren, Brandeis University) and cultured for 4 days with LPS. 
IRF4-/- B cells generated almost 6-fold fewer ASCs than WT, displaying a more 
severe impairment than Pim 1-/-2-/- B cells (Figure 5.6 D). The defect in ASC 
generation despite equal induction of activation markers, cell counts, and 
proliferation indicate that Pim 1 and/or 2 play an important role the differentiation 
pathway of an activated B cell to an antibody-secreting cell.  
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Figure 5.5. Induction of early activation markers is unimpaired in Pim 
1-/-2-/- B cells. Splenic B cells isolated from WT and Pim 1-/-2-/- mice were 
cultured with LPS, anti-CD40, or anti-IgM for 24 hours then analyzed by flow 
cytometry for CD69 and CD71 expression or 48 hours before analysis for CD95 
expression. Plots represents 3 separate experiments. Red lines are unstimulated 
controls, blue lines are stimulated cells.  
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Induction of early activation markers is unimpaired in 
Pim 1-/-2-/- B cells 
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Figure 5.6. Despite normal live cell counts and proliferation Pim 1-/-2-/- B 
cells generate significantly fewer ASCs. Splenic B cells isolated from WT, Pim 
1-/-, Pim 2-/-, and Pim 1-/-2-/- mice were cultured with LPS for 4 days. (A) Live cells 
were counted in each culture using trypan blue exclusion. Data includes 3 
experiments. (B) WT and Pim 1-/-2-/- B cells were stained with CFSE on day zero. 
Proliferation was monitored by CFSE dilution; day 4 with LPS is shown. Data 
represents 3 experiments. (C) ASCs were enumerated by ELISpot. Graph 
includes 3 experiments; statistics were determined by student’s t test *=p<.05, 
**=p<.01, ***=p<.001. (D) IRF4-/- and WT B cells were cultured for 4 days with 
LPS, ASCs were enumerated by ELISpot. Graph represents 2 separate 
experiments. 
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Fewer Pim 1-/-2-/- B cells express BLIMP-1 
Upon commitment to the ASC pathway, many genes are turned on or off 
in the B cell. Several key transcription factors have been identified that contribute 
to the ability of a B cell to differentiate into an ASC. In predicted order of 
expression, IRF-4, BLIMP-1 and XBP-1 are important for a B cell to differentiate 
into an ASC. A loss of any of these transcription factors decreases the ASC 
number found in the mouse (17, 19, 21, 46). BLIMP-1 in particular has been 
called the master regulator because its loss impairs ASC development and its 
over-expression pushes B cells to become ASCs.  
To further investigate where Pim 1 and 2 affect the ASC pathway, we 
measured the expression of these key transcription factors in ASC differentiation. 
IRF4 protein expression was measured using intracellular staining and FACS 
analysis. Pim 1-/-2-/- and wild type B6 B cells were cultured with LPS for the 
indicated times, harvested and stained for IRF4. B cells cultured with BLyS alone 
were used as negative controls. Pim 1-/-2-/- and B6 B cells showed the same 
levels of IRF4 over the time course tested (Figure 5.7 A) demonstrating that the 
loss of Pim 1 and 2 does not affect IRF-4 induction. 
To look further downstream in the ASC differentiation pathway, we 
measured BLIMP-1 induction. For this analysis we took advantage of a  
BLIMP-1gfp/+ mouse and crossed it to our Pim 1-/-2-/- mouse. The resulting B cells, 
BLIMP-1gfp/+ Pim 1-/-2-/-, mice allow us to measure the number of cells expressing 
BLIMP-1 by measuring the GFP expression by flow cytometry. B cells were 
isolated from BLIMP-1gfp/+ Pim 1-/-2-/- and control mice and cultured with BLyS 
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with or without LPS (Figure 5.7B). Three days after activation with BLyS+LPS 
control cultures contained an average of 6.2% GFP+ B cells while Pim 1-/-2-/- 
cultures contained on average only 1.3% GFP+. The difference was greatest on 
day 4; control cultures were 17.9% GFP+ more than 3-fold higher than Pim 1-/-2-/- 
cultures at 5.4% GFP+. By day 5 the GFP+ percentage in both control and  
Pim 1-/-2-/- cultures increased to 29.5% and 20.63% respectively. Both cultures 
plateau on days 6 and 7. Despite the increase on day 5 the percent of B cells 
expressing BLIMP-1 was significantly depressed in Pim 1-/-2-/- cultures compared 
to B6 controls on each day measured after activation with BLyS + LPS (Figure 
5.7 B). These results indicate the step, at which ASC generation is restricted in 
Pim 1-/-2-/- B cells, is induction of BLIMP-1. We also analyzed the geometric mean 
fluorescent intensity (MFI) of the GFP+ cells from Pim 1-/-2-/- and control cultures 
as a means of comparing how much blimp protein was made on a per cell basis. 
With the exception of day 3 in culture, the geometric MFI of the Pim 1-/-2-/- GFP+ 
B cells was significantly less than WT. Recent publications have suggested that 
increased expression of IRF4 induces BLIMP-1 expression and the Pim 2 is a 
target of IRF4 (71). These new insights suggest a mechanism by which Pim 1 
and/or 2 are critical for IRF4 induction of BLIMP-1. 
Although previous experiments had shown that cell counts on day 4 were 
equivalent in control and Pim 1-/-2-/- B cell cultures, we could not explicitly rule out 
the possibility that a survival impairment only within the small ASC subpopulation 
in each culture might be missed by this method. Because we now had the ability 
to identify ASCs in the culture using GFP expression, we revisited the survival 
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question. In each culture we measured the percent of dead cells with propidium 
iodide, combined with GFP expression we were able to identify dead cells within 
and outside the ASC population. We found that both the GFP+ and GFP- dead 
cell percentages were equal in control and Pim 1-/-2-/- cultures (Figure 5.7 C and 
D). Consistent with our previous data, this is consistent with the notion that there 
is not a survival defect in these cultures and the diminished number of ASCs is 
due to an inability to induce BLIMP-1 expression.  
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Figure 5.7. BLIMP-1 but not IRF-4 expression is impaired by the loss of Pim 
1 and 2. B cells isolated from BLIMP-1gfp/+ Pim 1-/-2-/- or control BLIMP-1gfp/+ mice 
were cultured in BLyS with or without LPS (A) The mean percent of IRF-4 
positive cells is given for each day (WT n=4 except day 5 when n=5; Pim 1-/-2-/- 
n=5 except day 5 when n=6) (B) The percent of GFP+ B cells in each culture is 
given, each symbol in a given day represents cells from one mouse, B cells 
isolated from a single mouse were measure over the 7 day time course, lines 
indicate mean and SEM, (WT n=4 except day 5 when n=5; Pim 1-/-2-/- n=5 except 
day 5 when n=4) (C) Cell death was also measured in GFP + and – populations 
by propidium iodide staining. Plots shown are from 4 days with LPS+BLyS and 
are representative of 3 experiments. The same results were obtained at each 
time point. (D) Geometric mean fluorescent intensity of GFP+ cells was 
determined for WT and Pim 1-/-2-/- samples at each time point. Pim 1-/-2-/- 
geometric MFI is plotted as a percent of WT controls. Graph includes 3 
experiments, lines indicate the mean and SEM, n=5 except day 5 when n=4. 
Statistics were determined by student’s t test *=p<.05, **=p<.01, ***=p<.001 
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Pim 1-/-2-/- GFP+ B cells behave as WT 
To examine the number of ASCs from the BLIMP-1gfp/+ Pim 1-/-2-/- or 
control BLIMP-1gfp/+ B cell cultures, GFP+ or GFP- cells were sorted by FACS and 
the number of ASCs was measured in each population. GFP- B cells were used 
as background controls and were always below 200 ASC/106 cells. ASCs/106 
GFP+ cells are plotted in figure 5.8. No significant difference was observed in the 
number of ASCs comparing WT and Pim 1-/-2-/- GFP+ cells at day 4 or 6, 
demonstrating that once a Pim 1-/-2-/- B cell is able to induce BLIMP-1, they are 
able to secrete antibody like the WT cells. 
To further examine different transcription factors required for ASC 
differentiation, RNA was also isolated from each sorted (GFP + or -) sample. We 
measured BLIMP-1 RNA using qPCR. No significant difference in RNA levels 
between Pim 1-/-2-/- GFP+ and control GFP+ cells was seen (Figure 5.9 A). From 
this we concluded that although the number of cells able to induce BLIMP-1 in 
Pim 1-/-2-/- cultures was significantly reduced the amount of BLIMP-1 mRNA 
expressed in GFP+ B cells was not. Though this seems to contradict our earlier 
observation of a depressed geometric MFI in the Pim 1-/-2-/- GFP+ B cell 
population, this could be due to translational control of BLIMP-1. 
We also analyzed these samples for expression of a third key transcription 
factor, XBP-1. XBP-1 is downstream of BLIMP-1 and IRF4 in the ASC 
differentiation pathway and experimental evidence suggests that losing either will 
block its expression (17, 19). XBP-1 expression levels were unaffected in the Pim 
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1-/-2-/- GFP+ B cells (Figure 5.9 B). This is not surprising considering that IRF4 
was unaffected in Pim 1-/-2-/- B cells and GFP+ B cells also displayed normal 
BLIMP-1 expression. 
Mcl-1 is a pro-survival molecule in the bcl-2 family that has been shown to 
be induced in antibody secreting cells (72) and by our lab to be downstream of 
Pim 2 (58) in naïve B cells. Consistent with our previous data on survival and 
GFP+ B cells, we found equal expression of Mcl-1 mRNA in control and Pim 1-/-2-
/- GFP+ B cell populations which was higher than that found in GFP- populations. 
The Mcl-1 expression in the GFP- populations was also comparable between 
controls and Pim 1-/-2-/- (Figure 5.9 C). Although significantly fewer Pim 1-/-2-/- B 
cells are able to induce BLIMP-1 expression compared to WT these data 
demonstrate that those that do express BLIMP-1 are completely normal. 
We began this chapter with the hypothesis that a B cell intrinsic defect 
was responsible for the impaired innate and TD humoral immunity described in 
chapters III and IV. Each experiment described here was consistent with this idea 
but not definitive. Culturing B cells alone allowed us to evaluate their intrinsic 
ability to differentiate into ASCs without outside influence. These experiments 
revealed a strong but incomplete block at BLIMP-1 induction in Pim 1-/-2-/- B cells 
cultured with LPS and demonstrated a B cell intrinsic defect with the loss of Pim 
1 and 2. 
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Figure 5.8. GFP+ WT and Pim 1-/-2-/- populations produce the same number 
of ASCs. WT BLIMP-1gfp/+ and Pim 1-/-2-/- BLIMP-1gfp/+ B cells isolated from 
individual mice were cultured with LPS and BLyS for 4 (WT n=3, Pim 1-/-2-/- n=4) 
or 6 (WT n=4, Pim 1-/-2-/- n=5) days before being sorted into GFP+ and GFP- 
populations. ASCs were measured by ELISpot, the GFP+ populations are shown, 
GFP- cells were used as background and ranged between 0 and 200 ASCs/106 
GFP- cells. Graph includes 3 experiments, lines indicate the SEM.  
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Figure 5.9. GFP+ Pim 1-/-2-/- B cells express normal levels of BLIMP-1, XBP-1, 
and Mcl-1. Splenic B cells isolated from BLIMP-1gfp/+ control and Pim 1-/-2-/- mice 
were cultured in LPS for 4 days then sorted based on GFP expression. RNA 
isolated from GFP+ and GFP- samples was measured by qPCR for relative 
expression of BLIMP-1 (A), XBP-1 (B), and Mcl-1 (C). Graphs are of one 
experiment but represent similar results from 3 separate experiments, WT n=2, 
Pim 1-/-2-/- n=2 lines indicate SEM. 
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Chapter VI 
Migration Of Pim 1-/-2-/- Cells 
Introduction  
Experiments in Chapter IV revealed impairment in TD responses due to 
the loss of Pim 1 and 2 kinases. The function of both T and B lymphocytes are 
important in mounting a TD response so a defect in either population would result 
in an impaired response. In Chapter IV we demonstrated that Pim sufficient T cell 
help was unable to rescue the TD response in Pim 1-/-2-/- mice, consistent with B 
cell defect. Another way to look at the function of T and B lymphocytes 
separately is to create a chimera. 
 Bone marrow chimera mice have been established as a useful tool for 
evaluating immune mechanisms (73). To produce chimeric mice, recipients are 
lethally irradiated to deplete host bone marrow stem cells before receiving 
transplant hematopoietic stem cells from bone marrow or fetal liver from one or 
more donor mice. Stem cells from bone marrow or fetal liver will home to the 
bone marrow microenvironment that sustains them then begin expanding. In the 
weeks to months following a bone marrow transfer the engrafted stem cells 
replace all the cells lost to the host mouse and can continue hematopoiesis for 
the rest of the mouse’s life. By using multiple donors it is possible to examine the 
behavior of specific deficient cell populations, such as Pim 1-/-2-/- B cells, in a WT 
157
environment. This approach would allow us to assess the individual contributions 
of B and T cell to the impaired TD response. 
By using donors that differ at the CD45 locus or Igh locus (allotype) 
marker we are able to identify the source of the peripheral lymphoid populations. 
In the work presented in this chapter, bone marrow or fetal liver from WT or Pim 
1-/-2-/- mice were transferred into a depleted host at various ratios, which enables 
us to observe the behavior of Pim 1-/-2-/- B cells after immunization in a 
completely sufficient environment created by the engraftment of WT stem cells.  
 While examining the immune response in chimera mice 12 weeks or less 
after reconstitution, we observed that WT cells seemed to be outcompeting  
Pim 1-/-2-/- cells during reconstitution. In addition we found that lethally irradiated 
mice reconstituted with Pim 1-/-2-/- bone marrow or fetal liver did not live past 2 
months suggesting that Pim 1-/-2-/- stem cells are unable to migrate normally 
preventing engraftment and survival.  
At the same time a paper was published showing that Pim 1-/- bone 
marrow cells are unable to reconstitute irradiated recipients due to a migratory 
defect. This migratory defect was attributed to deregulation of CXCR4 on the 
surface of these cells (44). CXCR4 is involved in early B cell development and 
organization of the germinal center as well as homing of bone marrow cells. 
Considering our observations that germinal centers in Pim 1-/-2-/- mice were 
impaired we asked whether homing of Pim 1-/-2-/- mature lymphocyte populations 
might also be affected. By transferring WT and Pim deficient splenocytes into 
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irradiated recipients we found that homing of mature Pim deficient splenocytes 
was unimpaired. 
Previously published work had shown that despite impairments in homing 
and engraftment fetal liver chimeras created by transferring a high number of 
CXCR4 fetal liver cells overcome this deficiency (45). We tried this approach with 
Pim 1-/-2-/- fetal liver cells but found that this did not overcome the impaired 
engraftment. These data suggest that other chemokines may be downstream of 
Pim 1 or 2 contributing along with deregulation of CXCR4 to the impaired 
engraftment of both bone marrow and fetal liver stem cells. 
 
Results  
Pim 1-/-2-/- reconstitution of peripheral lymphocyte populations is inefficient 
The first set of chimeras was created by injecting mixtures of Pim 1-/-2-/- 
(Ly5.2) and B6 wild type (Ly5.1) into lethally irradiated B6 wild type recipients 
(Ly5.1). Bone marrow from B6 Ly5.1 control and B6 Ly5.2 Pim 1-/-2-/- mice were 
combined at 3 different ratios (10:90, 50:50, and 90:10). A total of 6 chimeras 
were generated for each ratio. For preliminary analysis of the chimeras at 12 
weeks after reconstitution peripheral blood from one mouse of each ratio was 
examined for Ly5.1 (WT) or Ly5.2 (Pim 1-/-2-/-) B cells. Very few B220+ cells in the 
mouse given 90% Pim 1-/-2-/- bone marrow expressed either Ly marker; B220+ 
cells from the 50:50 recipient were equally distributed (47% Ly5.2+ and 46% 
Ly5.1+) and B220+ cells from the 10% Pim 1-/-2-/- recipient were over 97% Ly5.1+. 
To assess function in TD responses each recipient was immunized with 50 µg of 
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NP-CGG in Imject Alum. Ten days after immunization mice were sacrificed and 
spleens, lymph nodes, and Peyer’s patches were analyzed for reconstitution and 
germinal center B cells (CD95+GL7+) by flow cytometry.  
The fraction of B cells derived from the Pim 1-/-2-/- bone marrow was 
highly variable but consistently less than the percent of Pim 1-/-2-/- in the bone 
marrow mix for almost every recipient. Out of 5 recipients who received 90%  
Pim 1-/-2-/- bone marrow only 1 had a splenic B cell pool with close to 90%  
Pim 1-/-2-/- B cells. The other individuals ranged from 56 to 60% bringing the 
mean percent Pim 1-/-2-/- B cells to 63% ± 5. B cells derived from Pim 1-/-2-/- bone 
marrow in the Peyer’s Patches was slightly higher ranging from 62 to 85%.  
Pim 1-/-2-/- B cell reconstitution of the lymph nodes varied considerably with 90% 
Pim 1-/-2-/- recipients ranging from 12 to 14% Pim 1-/-2-/- B cells (Figure 6.1 A). In 
individuals who received 50% Pim 1-/-2-/- bone marrow the percent of Pim 1-/-2-/- 
derived B cells in the lymph nodes ranged from 2 to 66% with 3/5 recipients 
below 20% Pim 1-/-2-/- B cells. In Peyer’s Patches of the same mice receiving 
50% Pim 1-/-2-/- bone marrow the fraction of Pim 1-/-2-/- derived B cells was also 
variable, ranging from 11 to 52.7% with a mean of 26.3% ± 6. Pim 1-/-2-/- B cells 
percentages in the spleens of 5 mice receiving 50% bone marrow mixtures 
ranged from 6.9 to 44.1% with a mean of 18.27% ± 5, a noticeable decrease 
from the 50% Pim 1-/-2-/- bone marrow transferred (Figure 6.1 A). Pim 1-/-2-/- B 
cells in the spleens of mice receiving 10% Pim 1-/-2-/- bone marrow contained less 
than 5% Pim 1-/-2-/- B cells (Figure 6.1 A). Peyer’s Patches in the same 
individuals varied greatly with 3 individuals having 5% or fewer, 1 individual 
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having 19%, and 2 individual slightly above 30% Pim 1-/-2-/- B cells. Lymph nodes 
isolated from these mice averaged 6.5% ± 2 of their B cells being Pim 1-/-2-/- 
where 3 mice were 2% or less, one was 7%, and 2 were more than 10% at 12 
and 13% (Figure 6.1 A). With few exceptions the contribution of Pim 1-/-2-/- cells 
to the B cell pool in these recipients fell below the percent of Pim 1-/-2-/- cells in 
the transferred bone marrow. Out of these results we must consider two things, 
one that poor reconstitution of Pim 1-/-2-/- B cells will skew the proportion of 
WT:Pim 1-/-2-/- B cells participating in a germinal center response in our bone 
marrow chimeras after immunization and second that WT bone marrow cells may 
have an advantage over Pim 1-/-2-/- bone marrow cells during reconstitution. 
Earlier in this dissertation we demonstrated a defect in the ability of Pim 1-
/-2-/- mice to generate germinal centers in response to NP-CGG. To examine the 
function of Pim 1-/-2-/- B cells during a TD response in a WT environment we 
immunized the bone marrow chimeras and identified GC B cells by flow 
cytometry.  In the reconstituted chimeras B cells that were participating in a 
germinal center reaction could be determined by cell Ly surface markers. In 
chimeras reconstituted with 50% and 10% Pim 1-/-2-/- mixtures WT GC B cells 
were above the unimmunized control (Figure 6.1 B). In chimeras given 90% Pim 
1-/-2-/- bone marrow mixtures, however, WT B cells were not above unimmunized 
levels most likely due to the low reconstitution of WT B cells (Figure 6.1 B). None 
of the chimeras contained Pim 1-/-2-/- GC B cells in numbers above the 
unimmunized controls (Figure 6.1 B). In all cases the percent of Pim 1-/-2-/- B cells 
in the periphery were less than the percent of Pim 1-/-2-/- bone marrow in their 
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representative mixture transferred, accordingly only mice reconstituted with 90% 
Pim 1-/-2-/- bone marrow had enough Pim 1-/-2-/- peripheral B cells to allow us to 
draw a conclusion about the behavior of Pim 1-/-2-/- B cells during a TD response 
in a WT environment.  In these mice reconstituted with a 90:10 Pim 1-/-2-/-:WT 
mixture, despite the majority of peripheral B cell originating from Pim 1-/-2-/- bone 
marrow, germinal center B cells were almost entirely wild type. This supported 
the idea that there is a B cell intrinsic defect in the Pim 1-/-2-/- B cells. 
One impediment to a full interpretation of our previous chimera results 
using WT Ly5.1 bone marrow was our inability to identify the contribution from 
the irradiated hosts that were also Ly5.1+. To circumvent this problem we 
produced a second set of chimeras in which we replaced the WT Ly5.1 bone 
marrow with µMT bone marrow, in these chimeras stem cells from µMT donors 
should reconstitute all cell types except the B cell pool, T cells derived from µMT 
bone marrow can provide normal T cell help to the Pim 1-/-2-/- B cells upon 
immunization 8-12 weeks after the bone marrow transfer.  
Our initial strategy was to reconstitute Ly5.1 WT mice receiving 600 rads 
2 times with 1.5x106 bone marrow cells mixed at 80% µMT and 20% Pim 1-/-2-/- 
or WT, the high percent of µMT bone marrow transferred ensures that all cells 
other than B cells originated from the µMT bone marrow while the B cell 
compartment is reconstituted by either Pim 1-/-2-/- or control WT cells in the two 
sets of chimeras. This, however, resulted in poor reconstitution of the mature 
splenic B cell pool in both Pim 1-/-2-/- and WT chimeras. To try and improve the 
efficiency of reconstitution we increased the percent of Pim 1-/-2-/- and WT bone 
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marrow cells and transferred a total of 3x106 cells at a 90% Pim 1-/-2-/- or WT and 
10% µMT into lethally irradiated (600 rads, 2 times) B6 Ly5.1 recipients. We 
found consistently good reconstitution of peripheral WT B cells but not Pim 1-/-2-/- 
B cells. Of the B220+ B cells we did identify in 90% Pim 1-/-2-/- 10% µMT chimeras 
only a fraction were Ly5.2+ and therefore identified as originating from Pim 1-/-2-/- 
bone marrow (Figure 6.2).  
We also mixed Pim 1-/-2-/- bone marrow and bone marrow from allotype 
congenic B6 (Iga Thy1a) mice at various ratios and increased the total number of 
cells transferred into irradiated B6 Ly5.1 mice (600 rads, 2 times) from 3x106 to 
5x106. Increasing the number of cells transferred was an attempt to overcome 
any difficulties in reconstitution by Pim 1-/-2-/- bone marrow. We consistently 
found, however, that peripheral B cells were not derived from the Pim 1-/-2-/- bone 
marrow even if 90% of the cells transferred were obtained from Pim 1-/-2-/- 
donors. Furthermore, we began to observe that these mice would become 
dehydrated and have a hunched posture 7-12 weeks after transfer and had to be 
euthanized. Although these chimeras did not die from radiation sickness, which 
takes about 10 days, the results do indicate a defect in Pim 1-/-2-/- done marrow 
reconstitution, which became more apparent when we increased the percent of 
Pim 1-/-2-/- cells transferred.  
We employed several strategies in trying to overcome this deficiency in 
reconstitution.  Table 6.1 illustrates the different chimeras that were attempted 
with the ratio and recipients; none resulted in consistent reconstitution of the Pim 
1-/-2-/- B cell pool. Together these data support the conclusion that Pim 1-/-2-/- 
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derived stem cells were unable to compete with WT stem cells in the generation 
of peripheral B cells. This may reflect a broader defect in Pim 1-/-2-/- cell homing.  
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Figure 6.1. Pim 1-/-2-/- peripheral B cells are less than expected and not 
found in the germinal center. (A) Lethally irradiated mice (600 rads, 2 times) 
were given WT (Ly5.1) or Pim 1-/-2-/- (Ly5.2) bone marrow i.v., the ratio of Pim 1-/-
2-/- bone marrow to WT bone marrow cells transferred is indicated on the x-axis. 
8-10 weeks later mice were sacrificed, the percent of Pim 1-/-2-/- B cells was 
determined by flow ctometry (B220+Ly5.2+) (y-axis) for each organ (x-axis) is 
indicated. 90% Pim 1-/-2-/- n=5 (spleen and Peyer’s Patches) n=4 (lymph nodes), 
50% Pim 1-/-2-/- n=6, 10% Pim 1-/-2-/- n=6 (B) The same mice from part A were 
immunized with 50 µg of NP-CGG absorbed to Imject Alum 10 days before 
sacrifice. The number of Pim 1-/-2-/- (B220+Ly5.2+) or WT (B220+Ly5.1+) GC B 
cells (CD95+GL7+) found in the spleen is depicted (y-axis) for each ratio 
transferred (x-axis). Different symbols were used to distinguish between imput 
Pim 1-/-2-/- percentage. 90% Pim 1-/-2-/- unimmunized n=1, immunized n=4, 50 
and 10% Pim 1-/-2-/- unimmunized n=2, immunized n=4. Lines represent mean 
and SEM, each symbol represents an individual mouse, data from 2 separate 
experiments. 
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Pim 1-/-2-/- peripheral B cells are less than expected and not found in the 
germinal center. 
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Figure 6.2. Reconstitution of the peripheral B cell compartment in Pim 1-/-2-/-
:µMT bone marrow chimeras is impaired. Lethally irradiated (600 rads, 2 
times) B6 Ly5.1 mice received 3x106 bone marrow cells at a 90% Pim 1-/-2-/- or 
WT and 10% µMT mixture. 12 weeks after cell transfer chimeras were sacrificed 
and the percent of B cells originating from Pim 1-/-2-/- and WT bone marrow were 
identified as B220+Ly5.2+ by flow cytometry. Plots are representative of 5 Pim 1-/-
2-/-:µMT chimeras and 3 WT:µMT chimeras. 
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Table 6.1. Various combinations of donors and hosts were used with 
multiple ratios to create Pim 1-/-2-/- / WT mixed bone marrow chimeras. Table 
6.1 depicts from left to right the source(s) of transferred bone marrow (donors), 
the ratio(s) at which the transferred bone marrow was mixed, and the recipients 
from all bone marrow chimera experiments. 
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Pim 1-/-2-/- bone marrow cannot reconstitute lethally irradiated recipients 
The pathology observed previously during chimera studies indicated that 
Pim stem cells competed poorly in the generation of peripheral B cells and that 
chimeras became ill or died weeks after transfer. Work by Grundler and 
colleagues demonstrated in an alternative system that bone marrow from Pim 1-/- 
donors was unable to reconstitute lethally irradiated mice due to a defect in 
sustained CXCR4 expression, a chemokine receptor critical for homing of the 
cells to the bone marrow (44).  This impairment may explain our difficulties in 
generating a reliable Pim 1-/-2-/- / WT mixed bone marrow chimera. We tested the 
ability of Pim 1-/-2-/- bone marrow to reconstitute lethally irradiated recipients by 
transferring 3x106 Pim 1-/-2-/- bone marrow cells without wild type bone marrow 
support. Indeed Pim 1-/-2-/- bone marrow cells were unable to rescue lethally 
irradiated recipients (Figure 6.3). Mice receiving Pim 1-/-2-/- bone marrow had a 
mean life expectancy of 23 days whereas 4 of the 5 mice receiving WT bone 
marrow cells lived until the experiment was terminated at 60 days.  
These results closely matched those previously published concerning Pim 
1-/- bone marrow studies, which suggested that a defect in CXCR4 was 
responsible for these observations (44). This suggested that our difficulties in 
creating a Pim 1-/-2-/- bone marrow chimera might also be due to a CXCR4 
defect. In addition to its role in homing of hematopoetic stem cells CXCR4 is 
essential for proper organization of the GC (45). CXCR4 migration defects may 
also be present in mature peripheral B cells. Considering the similarities between 
our observations and the published results by Grundler et al with the continued 
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role of CXCR4 in mature B cells we tested the homing efficiency of mature Pim 1-
/-2-/- B cells. 
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Figure 6.3. Pim 1-/-2-/- bone marrow cannot rescue lethally irradiated 
recipients. C57BL/6 mice were lethally irradiated receiving 900 rads followed by 
transfer i.v. of 3x106 bone marrow cells from either WT or Pim 1-/-2-/- or no cells 
24 hours later. Survival is plotted over 70 days. 
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Pim 1 and/or 2 deficient mature splenocytes migrate normally 
Pim 1-/-2-/- B cells developing in chimeras in what should be a supportive 
environment for TD responses fail to participate in a GC response (Figure 6.1 B). 
Given the published CXCR4 impairment in Pim 1-/- bone marrow cells (44) which 
closely matched our own reconstitution results, and the role for CXCR4 in the 
germinal center (45) it is possible that CXCR4 migration defects may also 
present in mature peripheral B cells. To investigate the homing capacity of 
mature B cells from Pim deficient mice we transferred mature splenocytes from 
Pim 1-/-2-/- or WT mice labeled with CFSE into lethally irradiated recipients.  
Twenty-four hours later spleens were harvested and the number of CFSE 
positive B cells determined by flow cytometry.  No significant difference was 
observed in recipients of Pim 1-/-2-/- cells (Figure 6.4 A). We were concerned that 
by irradiating the recipients we had created space for the cells to flow freely 
regardless of possible homing defects. Therefore the experiment was repeated 
using un-irradiated recipients. Splenocytes from Pim 1-/-, 2-/-, 1-/-2-/-, and control 
mice were labeled with CFSE and transferred into un-irradiated recipients. 
Twenty-four hours later we examined the spleen and bone marrow for CFSE 
labeled B cells as before. No difference was observed in the ability of mature 
splenic B cells of any genotype to home to the spleen or bone marrow (Figure 
6.4 B). Although the inability of Pim 1-/-2-/- bone marrow to rescue lethally 
irradiated recipients is consistent with a homing deficiency in those cells we have 
found no evidence of a homing defect in mature splenic Pim 1-/-2-/- B cells.   
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Figure 6.4. Pim 1 and/or 2 deficient mature splenocyte migrate normally. (A) 
CFSE labeled splenocytes from Pim 1-/-2-/- or control mice were transferred i.v. 
into B6 mice exposed to 900 rads 24 hours previous. 24 hours after transfer 
recipients were sacrificed and the number of CFSE+ cells in the spleen 
determined by flow cytometry. For each bar n=5 (B) CFSE labeled splenocytes 
from Pim 1-/-2-/-, Pim 1-/-, Pim 2-/- or WT mice were transferred into intact B6 mice, 
24 hours later recipients were sacrificed. The number of CFSE+ cells in the bone 
marrow and spleen were determined by flow cytometry. For each bar n=3. No 
significant difference was found in either experiment. 
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Pim 1 and/or 2 deficient mature splenocyte migrate normally 
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Pim 1-/-2-/- fetal liver cells do not reconstitute peripheral populations   
Work on CXCR4 deficient mice had shown that their inability to 
reconstitute irradiated recipients could be overcome by using high numbers of 
fetal liver cells, which successfully results in viable chimeras (45). We 
hypothesized that if Pim 1-/-2-/- bone marrow cells were unable to reconstitute 
lethally irradiated recipients due to a CXCR4 functional defect as in Pim 1-/- bone 
marrow cells described previously (44) then transferring a high number of fetal 
liver cells would allow us to create WT:Pim 1-/-2-/- chimeras.  
We transferred 10x106 fetal liver cells collected from control Iga Thy1a or 
Pim 1-/-2-/- Igb Thy1b mice at a 20:80 or 50:50 WT:Pim 1-/-2-/- ratio into B6 Rag-/- 
mice. 12 weeks after cell transfer the percent of peripheral B cells originating 
from WT or Pim 1-/-2-/- fetal liver stem cells were determined by flow cytometry. 
Our results show the emergence of IgMa (WT) but not IgMb (Pim 1-/-2-/-) B cells in 
the spleen (Figure 6.4).  T cell reconstitution was more variable, Pim 1-/-2-/- fetal 
liver derived (Thy1.2) T cells were the only T cells detected in one chimera while 
the majority of T cells in the other chimeras originated from WT (Thy1.1) fetal 
liver (Figure 6.4). 
We attempted to create fetal liver chimeras again using only a 80:20 Pim 
1-/-2-/-:WT mixture to favor Pim 1-/-2-/- reconstitution, we also allowed more time 
for reconstitution than in the first experiment and irradiated (600 rads, 2 times) 
the B6 Rag-/- recipients. Pim 1-/-2-/- Igb fetal liver cells and (due to the 
unavailability of Iga fetal liver) WT Iga bone marrow cells were transferred into 
lethally irradiated recipients at an 80:20 ratio.  Despite the high number of cells 
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transferred and the WT bone marrow cells included in the mixture these 
chimeras died within 2 months (Figure 6.5). Furthermore many of these mice 
demonstrated symptoms we saw in the Pim 1-/-2-/- bone marrow chimeras 
described earlier in this chapter including dehydration, and hunched posture and 
had to be euthanized as a result. These results lead us to conclude that Pim 1-/-2-
/- fetal liver and bone marrow cells are unable to reconstitute recipients. Our 
observations when transferring Pim 1-/-2-/- bone marrow into lethally irradiated 
recipients closely mimicked those published by Grundler and colleagues 
demonstrating impaired Pim 1-/- bone marrow reconstitution due to a CXCR4 
defect. However, transferring Pim 1-/-2-/- fetal liver cells, even in high numbers, 
which has been shown to overcome the loss of CXCR4, was insufficient to 
rescue the defect preventing reconstitution by Pim 1-/-2-/- stem cells.  This 
suggests that either a defect in CXCR4 is not responsible for the impairment in 
Pim 1-/-2-/- stem cells or it is only one of multiple defects caused by the loss of 
both Pim 1 and 2, which prevent reconstitution by stem cells from either bone 
marrow or fetal liver.   
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Figure 6.5. Pim 1-/-2-/- fetal liver cells do not reconstitute peripheral B 
cells. Control Iga and Pim 1-/-2-/- Igb fetal liver cells collected 14 days into 
gestation were transferred i.v. into B6 Rag-/- mice at a 20:80 ratio. At 12 weeks 
post transfer mice were sacrificed and splenic B cell (A) and T cell (B) 
populations were examined by flow cytometry.  
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Pim 1-/-2-/- fetal liver cells do not reconstitute peripheral B cells.
A. 
 
 
 
B. 
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Figure 6.6. Pim 1-/-2-/- fetal liver cells do not reconstitute lethally 
irradiated recipients. Pim 1-/-2-/- fetal liver cells collected on day 14 of gestation 
and WT Iga bone marrow cells at an 80:20 ratio were transferred i.v. into lethally 
irradiated B6 rag-/- mice. The percent of surviving mice (y-axis) is plotted for day 
after reconstitution (x-axis) (n=12). 
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Chapter VII 
 
Discussion 
 
 
Despite the many roles of Pim 1, 2, and 3, mice deficient in all three 
kinases did not show any gross abnormalities (52). This may be due to 
redundancy in signaling pathways. For example, Pim 1-/-2-/- T lymphocytes 
behave normally in vitro until the Akt pathway is blocked with rapamycin, which 
reveals a role for Pim 1 and 2 in T cell activation and proliferation (42). Pim 1-/-2-/- 
and 2-/- naive B lymphocytes survival normally in culture in the presence of BLyS 
unless treated with rapamycin. When Akt was inhibited, Pim 2 was defined as the 
critical kinase for BLyS dependent B cell survival (58). Given the role of Pim 1 
and 2 in T cell activation and the survival of naïve B cells, we asked whether B 
cells required Pim 1 and/or 2 after activation for differentiation to antibody 
secretion or memory cells. Consistent with a role for Pim 1 and 2 in activated B 
cells, we demonstrated that Pim 1 and 2 were induced in B cells activated in 
culture with various mitogens. The immune response of Pim 1-/-2-/- mice had not 
previously been investigated. After immunization with both T cell dependent and 
independent antigens, we found a significant impairment in antigen specific 
antibody, germinal center formation, and ASCs in the Pim DKO mice. This is the 
first time a phenotype has been described for the loss of Pim 1 and 2 when Akt 
activity is intact. To further pursue the mechanism(s) for this phenotype, we have 
examined the humoral immunity in naïve and immunized Pim deficient mice. 
Functions of the humoral immune response, which we have found to rely on Pim 
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1, Pim 2, or both kinases are summarized in figure 7.1. All our observations in 
Pim single and double deficient mice are summarized in table 7.1. The evidence 
presented in this dissertation has led us to a model in which Pim 1 or 2 are 
critical for the induction of BLIMP-1 interrupting the antibody secreting cell 
differentiation pathway which effects several facets of humoral immunity (Figure 
7.2).  
Induction of Pim 1 and 2 was observed after B cell activation by LPS, 
CpG, anti-delta dextran, anti-CD40, anti-IgM, and the TI-2 antigen TG4. This 
diverse group of stimuli mimic, as best we can in vitro, activation pathways used 
by TI-1 (LPS and CpG), TI-2 (TG4, anti-delta dextran, anti-IgM) and TD (anti-IgM, 
anti-delta-dextran, and anti-CD40) antigens during B cell activation in vivo. These 
activators bind either TLR4, TLR9, BCR, or CD40 whose downstream signaling 
includes both overlapping and divergent targets. The fact that these receptors 
take part in different immune responses - for example TLRs are involved in TI-1 
responses while CD40 is involved in TD responses - highlights their differences 
and separate roles in the B cell. It also raises the possibility that although Pim 1 
and 2 are induced by activation of each receptor, it may play a different role in 
the cell depending on which receptor was activated. This idea is further 
supported by our observation that the TD and TI responses in Pim 1-/-2-/- mice 
are not equal. While both responses signal through the BCR, only TD antigens 
elicit signals through CD40, suggesting that Pim 1 and 2 may play different roles 
downstream of these 2 receptors. Furthermore, the defects we observed in the 
single knockout mice after immunization with a TI-2 or TI-1 antigen were not the 
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same. Although Pim 1-/- mice produced significantly fewer antibodies than WT 
early after a TI-1 immunization, however, the early stages of the TI-2 response 
were unperturbed. This would be consistent with divergent roles for Pim 1 
downstream of TLRs, involved in TI-1 responses, and the BCR, required for TI-2 
responses. The signaling pathways which connect these receptors to Pim 1 and 
2 induction remains an area of active investigation but will likely shed some light 
on our differing observations during in vivo immune responses.    
 
In response to immunization with a TD antigen mice deficient in either Pim 
1 and/or 2 have significantly decreased antigen specific antibody, antibody 
secreting cells, and germinal centers. To determine if this was due to an impaired 
mature lymphocyte pool we analyzed the splenic B and T cell subpopulations. 
Since the number of both marginal zone and follicular splenic B cell populations 
are intact in the fully B6 backcrossed Pim KO mice, the problem with the immune 
response is more likely intrinsic to the B cells. When we analyzed mature splenic 
T cell numbers in the C57BL/6 Pim 1-/-2-/- mice, a slight decrease in the CD8+ but 
not the CD4+ T cell number was observed. Therefore, a T cell effect on humoral 
immunity in these mice is less likely. These observations do not explain the 
significant impairment observed in antibody titer. We also observed that the 
serum antibody in naïve Pim 1-/-2-/- mice was consistently lower than that of naïve 
WT controls, which suggests that there may be a B cell intrinsic defect in 
antibody generation due to this genetic deficiency.  
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When we examined the B1 B cell populations in the peritoneal cavity that 
are the source of natural antibody, we did find a significant decrease in B1 B cell 
numbers that may explain the reduced levels of IgM, IgG3, and IgA in naïve Pim 
1-/-2-/- mice. One possible explanation for this diminished peritoneal B cell 
population, which includes B1a and B1b, as well as some B2 cells, is that the 
generation of these cells from a common precursor is impaired by the loss of Pim 
1 or 2. Fetal liver preferentially reconstitutes the peritoneal B cell compartment 
while bone marrow preferentially reconstitutes the splenic B cell compartment. 
This suggests that these two groups of B cells can originate from separate 
precursor cells so the loss of Pim may impair the generation of peritoneal B cells 
but not splenic B cells. Another possibility is that the loss of Pim 1 or 2 disrupts 
signaling downstream of the BCR and other receptors required for the 
commitment of B cell precursors to become peritoneal B cells. Mutations in 
positive regulators of BCR signaling such as btk and CD19 as well as some B 
cell transcription factors, for example NFATc, have been shown to decrease the 
number of B1 cells (9). These mutations generally results in the diminution of 
only one subset of peritoneal B cells but our in vitro experiments demonstrated 
that Pim 1 and 2 were induced upon stimulation by many receptors suggesting 
that the loss of either of these kinases could interrupt a number of the signaling 
pathways thereby affecting multiple peritoneal B cell subpopulations.  
B1 B cells in the peritoneal cavity produce natural IgG3 and IgM but 
migrate to the intestine before producing IgA. IgA is mainly attributed to mucosal 
immunity; in particular the gut associated lymphoid tissue (GALT) including 
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Peyer’s Patches. When we examined Peyer’s Patches from Pim 1-/-2-/- mice, we 
found a significant decrease in the number of B cells from 3.5x106 ± .4 to 1.3x106 
± .2 and about half as many IgA+ B cells compared to controls. Interestingly, we 
also found significantly fewer germinal center B cells by FACS analysis, matching 
our observation that the generation of germinal centers in the spleen was 
impaired during a TD response. So during antibody response to both 
environmental antigens and immunization Pim 1-/-2-/- mice have deficient 
germinal centers. 
Germinal centers in the spleen are a hallmark of a TD response. We 
observed that under most circumstances Pim 1-/-2-/- mice produced few if any 
GCs though this defect could be overcome in some mice with the use of a 
stronger antigen or adjuvant. Using Imject Alum as an adjuvant, Pim-deficient 
animals consistently did not produce GC B cell populations as examined by flow 
cytometry, nor did they have PNA+ GCs in spleen sections examined by 
immunohistochemistry. A few Pim deficient mice immunized with NP-CGG that 
had been precipitated in alum produced some GCs although there were non-
responders with no GC B cells or PNA+ GCs in the same group.  Those mice 
that did generate GCs produced normal numbers compared to wild type. These 
“all or nothing” observations have led us to propose a few possibilities to explain 
our GC data. 
One hypothesis is that signaling cascades that include Pim 1 and 2 
kinases downstream of the BCR and CD40 lower the threshold of activation in a 
B cell. The loss of Pim, therefore, would prevent efficient B cell activation unless 
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there is increased signal strength either downstream of BCR, CD40, or another 
receptor pathways were able to compensate. This would potentially allow for the 
normal formation of GCs in some mice where there may be an environmental 
stimulus in conjunction with the immunization allowing the B cell to reach a 
threshold of activation despite the loss of Pim 1 and 2. This hypothesis is 
consistent with our observation that early in a TD response the affinity of 
antibody from Pim 1-/-2-/- mice is significantly higher than WT suggesting that only 
the high affinity B cells present in the Pim 1-/-2-/- pool are being activated because 
their higher affinity BCR produces a stronger signaling. Our in vitro data 
demonstrates that Pim 1-/-2-/- B cells are capable of normal activation and 
proliferation, which argues that the in vitro conditions used for those experiments 
were very strong, unlike an antigen in vivo, which can only activate B cells with 
BCR specificity to that antigen. Indeed, preliminary in vitro experiments using 
sub-optimal activator concentrations shows that Pim DKO B cells have delayed 
proliferation, determined by CFSE dilution, compared to wild type B cells. Further 
studies to confirm this observation are ongoing. 
FACS analysis of splenic B cells from the in vitro cultures also 
demonstrated that Pim 1-/-2-/- B cells increased expression of CD95 normally 
upon activation. During a TD response, signaling downstream of CD95 results in 
cell death unless B cells receive appropriate survival signals from the BCR or 
CD40 receptors. Considering that Pim 1 and 2 are downstream of both of these 
receptors and that Pim 2 has been shown to play a role in survival of naïve B 
cells another possibility problem with GC formation is the survival of activated 
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Pim 1 and 2 KO B cells. The loss of Pim 1 and 2 may render the activated B cell 
(which is now expressing CD95 on its surface) more susceptible to CD95 killing, 
preventing the B cells from living long enough to form a GC. 
It is also possible that GC formation is impaired due to defective B cell 
migration. There have been several examples of this in the literature. Recently 
S1P2 was shown to promote clustering and migration of GC B cells to retain 
normal size and shape of the GC structure. Although GCs do form in S1P2-
deficient mice, deficient GC B cells were found at or outside the GC perimeter 
more often than were WT B cells (74). In CXCL13-deficient mice, GC can also be 
found, though they are smaller and less organized than those found in WT mice 
(45). Combining these defects by transferring S1P2-deficient B cells into 
CXCL13-deficient mice followed by TD immunization reveals a loss in GC 
formation (74). Pim 1-/- bone marrow cells have impaired migration due to 
decreased cell surface expression of CXCR4 (44), a receptor, which is also 
important in the organization of germinal centers (45). Cell transfer experiments 
revealed that homing of mature splenic Pim DKO B cells was normal (Figure 
6.4). These data suggest that GC formation and organization are dependent on 
multiple signals both intrinsic and extrinsic to the B cell, which may explain why 
we do not see a complete ablation but a decrease in GCs in Pim 1-/-2-/- mice.  
So how does GC formation occur in some Pim DKO mice when they 
receive a stronger antigenic signal? The response to a TD antigen requires the 
interaction of B and T cells so it is possible that a T cell, and not B cell, defect is 
responsible for the impaired GC response. To ask if WT T cell help would 
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alleviate the impaired TD response, we transferred WT T cells specific to OVA 
into Pim 1-/-2-/- or control mice then immunized with NP-OVA. The response in 
Pim 1-/-2-/- mice was not improved by the addition of WT T cell help 
demonstrating that Pim 1-/-2-/- T cells are not the likely cause of the deficiency. 
This is consistent with our idea that Pim DKO B cells have an intrinsic B cell 
defect but does not rule out the possibility of defects in both T and B lymphocytes 
exacerbate the problem in GC formation. 
To study the possibility of an intrinsic B cell defect, we determined if B 
cells could respond normally to antigen when T cell help was not needed. Pim 1-/-
2-/- mice immunized with TI-1 or TI-2 antigens had impaired antibody responses. 
Pim 1 and 2 seem to play diverging roles in TI responses as the antibody 
responses of the single knockouts were different from WT, Pim 1-/-2-/-, and each 
other. All these antigens were delivered i.p., therefore the responses are 
influenced by peritoneal B cells in TI-2 responses (70). To circumvent the 
peritoneum and determine if the TI-2 impairment was due to the decreased 
peritoneal cavity B cell numbers, we immunized Pim deficient mice with NP-Ficoll 
i.v. which is delivered directly to the splenic marginal zone B cells. The response 
of Pim single knockout mice was the same as wild type under these conditions; 
however, the TI-2 response in Pim 1-/-2-/- mice was still decreased. The 
observation that antigen delivered to the marginal zone B cell population which 
we know to be numerically intact did not induce an immune response again 
supported our hypothesis of an intrinsic B cell defect. 
191
A B cell’s response to stimulation can be tested directly in vitro. WT and 
Pim 1-/-2-/- B cells were isolated and cultured with various mitogens to examine 
activation. Induction of activation markers, proliferation, and cell survival were 
normal in activated Pim 1-/-2-/- B cells, however, Pim 1-/-2-/- cultures produced 
significantly fewer ASCs. In the future we would like to examine these 
parameters in vivo. Using NP-APC to detect NP-specific B cells by flow 
cytometry in naïve vs. Pim 1-/-2-/- mice, we can ask whether the number of 
precursors has been altered. NP-APC will also allow us to detect NP-APC 
specific B cells during a TD response to NP-CGG and track their proliferation by 
administering BrdU. If WT and Pim 1-/-2-/- NP specific B cells are dividing equally 
from a comparable number of precursors than the number of BrdU+ cells will be 
equal. Activation markers can also be measured by flow cytometry on this same 
population. By performing these experiments on BLIMP-1gfp/+ mice we can also 
measure the number of NP specific BLIMP-1+ B cells, which have committed to 
the plasma cell lineage by flow cytometry. Alternatively, ASCs can be measured 
ex-vivo by ELISpot. Survival can be measured within a NP specific B cell 
population at each stage using P.I. or one of many cell survival dyes made for 
flow cytometry. If consistent with our in vitro results we would expect to see no 
difference in the proliferation, induction of activation markers, or survival 
concurrent with a drop in GFP+ Pim 1-/-2-/- B cells by facs and of Pim 1-/-2-/- ASCs 
by ELISpot. 
Having observed that Pim 1-/-2-/- B cells were able to recognize antigen 
and proliferate but that antibody and ASC numbers were decreased in response 
192
to TI antigens and in vitro activation, we hypothesized that the B cells were 
unable to differentiate to the antibody secreting cell lineage. Impairment in the 
ability of B cells to differentiate into ASCs would impact any humoral response in 
naïve and immunized mice. WT and Pim 1-/-2-/- B cells were cultured with LPS 
and the number of ASCs was measured by ELISpot. A clear deficiency was 
observed in Pim 1-/-2-/- but not single knock out B cells, matching our previous 
observation using i.v. immunization.  
To try to identify which step in ASC differentiation Pim 1-/-2-/- B cells were 
blocked, we took advantage of a BLIMP-1gfp/+ mouse. Pim 1-/-2-/- BLIMP-1gfp/+ and 
control B cells were cultured in vitro with LPS and induction of 2 key transcription 
factors, IRF-4 and BLIMP-1, were measured by flow cytometry. These 
experiments revealed that Pim 1-/-2-/- B cells were able to express normal levels 
of IRF4 but not BLIMP-1, which is the master regulator of ASC generation. A 
recent publication identified Pim 2 as a target of IRF4 in plasma cells (71); our 
data suggests that Pim 1 is able to compensate for this loss as single knock out 
mice generated normal ASC numbers in vitro. Taken together these data reveal 
a model where Pim 1 or 2 is required downstream of IRF4 for the induction of 
BLIMP-1 (Figure 7.2). BLIMP-1 is critical for the complete differentiation to the 
plasma cell lineage due to its ability to induce genes necessary for plasma cell 
function and extinguish genes associated with mature B cells (18). This block in 
the generation of ASCs inhibits the B cell response to TI and TD antigens as well 
as the production of natural antibody as BLIMP-1 is required for antibody 
production by B1 cells as well as B2 cells (43). Our current model depicting how 
193
Pim 1 and 2 are involved in BLIMP-1 induction is depicted in figure 7.2. The 
model also includes several other players, which must be considered when 
thinking about ASC generation. MicroRNA-155 (75) for example has been shown 
to down regulate PU.1 a transcription factor that positively regulates BLIMP-1 
(76). No direct connection of miRNA155 to Pim kinases has been shown to date, 
however, we are currently testing RNA isolated from WT and Pim 1-/-2-/- ASCs to 
determine if regulation of either of these factors is disrupted with the loss of Pim 
1 and 2. Deregulation of c-myc impairs ASC generation (77), under normal 
conditions c-myc is repressed by BLIMP-1 (6). Bcl-6 and Pax-5 are also known to 
be repressed by BLIMP-1 (6) and would therefore be expected to be higher in 
Pim 1-/-2-/- B cells unable to induce BLIMP-1 though this has not yet been tested. 
The inability of Pim 1-/-2-/- B cells to differentiate into ASCs does not 
explain why Pim 1-/-2-/- B cells do not isotype switch efficiently despite normal 
levels of sterile transcripts and AID mRNA levels. A number of AID co-factors 
have been implicated in CSR though biochemical evidence is scarce (65). Indeed 
the aberration of any one of these components due to the loss of Pim 1 and 2 
may be responsible for the decrease in isotype switching we have observed. 
However, because AID is unquestionably required for both isotype switching and 
affinity maturation, which is also impaired in Pim 1-/-2-/- mice, we have focused 
our attention there. Even focusing on AID alone there are several steps, which 
could be impacted. Although AID expression in Pim 1-/-2-/- B cells, which fail to 
switch, appears at WT levels we have yet to determine where it is localized. AID 
is transported to the nucleus after BCR stimulation (which also induces Pim 1 
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and 2) but the mechanisms regulating this transport are not fully elucidated and 
so could involve Pim 1 and/or 2 (65). In addition to transcriptional and localization 
control, post-translational control is critical to AID regulation. Phosphorylation at 
serine and threonine residues regulates AID activity and mutations at these 
residues have been shown to interfere with isotype switching and somatic 
hypermutation, critical to affinity maturation (66). Given the requirement for 
serine/threonine phosphorylation of AID for normal isotype switching and somatic 
hypermutation and the established role for Pim 1 and 2 as serine/threonine 
kinases we hypothesized that Pim 1 or 2 kinases modify AID protein thereby 
affecting the level of isotype switching and affinity maturation. We are currently 
pursuing this idea.  In this scenario it seems likely that the same mechanism is 
responsible for the loss of isotype switching and affinity maturation we observed 
in the Pim 1-/-2-/- TD response. However, unlike our observations on isotype 
switching, our observation of impaired affinity maturation was only in vivo and 
cannot be definitively linked to a B cell intrinsic defect. Alternatively affinity 
maturation during the TD response to NP may have been absent because of the 
impaired germinal center response, where affinity maturation generally takes 
place. However it has been demonstrated that affinity maturation can occur 
normally without germinal centers (78), suggesting that like isotype switching the 
defect in affinity maturation is intrinsic to the Pim 1-/-2-/- B cell. 
This work is the first demonstration of impaired function due to the loss of 
Pim 1 and/or 2 when Akt is intact. We have also elucidated a previously unknown 
and critical role for Pim kinases in humoral immunity. The novel discoveries in 
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this dissertation expands our basic understanding of B cell function and impacts 
both the investigation of immunodeficiencies in humans as well as the field of 
cancer research where Pim 1 and 2 have been suggested to be good drug 
targets in cancer therapy.  
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Figure 7.1. Humoral immune functions that rely on Pim 1 alone, Pim 2 
alone, or either. This ven diagram depicts functions of the humoral immune 
system, which we have determined to rely on Pim 1 (left), Pim 2 (right), or to be 
intact when either Pim 1 or Pim 2 (center) is present. 
 
Humoral immune functions that rely on Pim 1 alone,  
Pim 2 alone, or either 
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Figure 7.2. Current model for Pim 1 and 2 involvement in BLIMP-1 
induction. Activation signals increase IRF4 expression early in ASC 
commitment, which we know to be intact in Pim 1-/-2-/- B cells. Pim 2 has been 
demonstrated to be a target of IRF4 in antibody secreting cells while our data 
indicate that Pim 1 is a suitable substitute. Pim 1 and 2 are required for normal 
BLIMP-1 induction though the molecular mechanism behind this remains unclear. 
Other components implicated in ASC differentiation are depicted as described in 
the literature. Pim 1 and 2 may also regulate MicroRNA-155. MircroRNA-155 
represses PU.1, which binds directly to BLIMP-1 to increase its expression. 
BLIMP-1 represses c-myc, Pax5, and Bcl-6 while inducing XBP-1 as part of the 
transition from GC to antibody secreting cell. XBP-1 induction relies on both 
BLIMP-1 and IRF4 increased expression. In this model we propose that Pim 1 
and/or 2 are required for BLIMP-1 induction as a direct target of IRF-4 and/or for 
the repression of miRNA155. Red lines indicate that a direct relationship has 
been demonstrated; dashed line was determined by our data. 
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Current model for Pim 1 and 2 involvement in BLIMP-1 induction 
 
 
 
 
 
 
 
199
 
 
 
Table 7.1 A summary of our observations in Pim single and double 
knock out mice. Percent is of the mean relative to WT, no difference is indicated 
as “100%”, Not done=ND.  
 
A summary of our observations in Pim single and 
double knock out mice 
 
 Pim 1-/- Pim 2-/- Pim 1-/-2-/- 
Splenic B cells  100% 100% 100% 
Splenic T cells  100% 100% 60% 
Peritoneal B2 B cells 20% 35% 20% 
Peritoneal B1a B cells 37% 45% 20% 
Peritoneal B1b B cells 30% 50% 25% 
“Natural” IgM  8% 6% 3% 
“Natural” IgG3  ND ND 16% 
“Natural” IgG1 100% 300% 100% 
“Natural” IgA 25% 100% 45% 
“Natural” IgE 100% 100% 100% 
GC B cells in Peyer’s 
Patches 
13% 47% 40%  
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IgA+ B cells in Peyer’s 
Patches 
2% 100% 23% 
IgM+ B cells in Peyer’s 
Patches 
11% 1% 25% 
TI-2 antibody Shortened 
response (i.p.) 
100% (i.v.) 
60% (i.p.) 
100% (i.v.) 
10% i.p. 
20% i.v. 
TI-2 ASCs SLPCs-ND 
LLPCs-60% 
SLPC-100% 
LLPCs-ND 
SLPCs-25% 
LLPCs-30% 
TI-1 antibody (Day 5) 30% 13% 10% 
Early Activation 
markers 
ND ND 100% 
Proliferation 100% 100% 100% 
In vitro ASC 
generation 
100% 100% 40% 
IRF4 induction ND ND 100% 
BLIMP-1 induction ND ND 20% 
In vitro survival  100% 100% 100% 
Bone marrow or fetal 
liver Reconstitution 
ND ND No 
Homing of mature 
splenocytes 
100% 100% 100% 
Germinal Center ND 100% 30% 
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formation 
IgM response to a TD 
antigen 
100% 20% 20% 
λ response to a TD 
antigen 
30% 30% 20% 
IgG1 antibody to a TD 
antigen 
25% 10% 10% 
ASC numbers in 
response to a TD 
antigen 
ND SLPCs- 50% SLPCs- 30% 
LLPCs- 8% 
Isotype switching 45% 80% 35% 
Sterile transcripts 100% ND 100% 
AID mRNA 100% ND 100% 
Affinity (> 6 months) ND ND 58% 
Response to 
secondary TD 
challenge 
ND ND 5% 
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